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ABSTRACT OF CAPSTONE 
Epidemiology of Colorectal Cancer Comorbidities and Stage at Diagnosis, 
Survival, and Second Primary Malignancies in Kentucky, 2003-2016 
Background: Colorectal cancer (CRC) is the third most common type of cancer and the third most 
common cause of cancer death among men and women in the United States.1-3  The American Cancer 
Society estimates that there will be 147,950 new cases of CRC and 53,200 CRC related deaths in the 
U.S. for the year 2020.3  Kentucky CRC incidence for 2012-2016 was the highest in the nation, and the 
mortality rate for years 2013-2017 was ranked 5th in the nation.4-6  Risk factors for CRC include 
lifestyle factors, genetics, and disease status (comorbidities and treatment).2, 7 Diabetes has been 
found to be the most prevalent comorbidity among CRC patients, and the risk of developing CRC in 
patients with diabetes is 25% higher than those without diabetes.8, 9   
Aim: The purpose of this study is to explore if comorbidities impacts CRC progression, CRC 
outcomes, and the development of second primary malignancy among CRC patients age 18 and older 
in Kentucky diagnosed between January 1, 2003 and December 31, 2016.  
Methods: Two studies were performed using CRC data from Kentucky Cancer Registry, one was a 
retrospective cohort study and the other was a case control study. There were 20,571 cases included 
in the cohort study with the primary outcomes was all-cause mortality, CRC mortality, and second 
primary cancer. There were 18,170 total, 9,085 cases and controls in the second study. This study 
examined the geographical distribution of late-stage CRC and comorbidities. 
Results Chapter 3: Logistic regression models show that comorbidities increased the odds of death 
or late-stage CRC. The Cox proportional hazard models of all-cause and CRC mortalities and second 
primary show that comorbidities, patient factors, and treatments can be protective or increase the 
hazards of dying or having a second primary cancer. The Kaplan Meier curve demonstrates the 
survival of early-stage at diagnosis CRC versus late-stage at diagnosis CRC. 
Results Chapter 4: The geographical distribution maps of the four positively associated 
morbidities (electrolyte disorders, liver disease, weight loss, and deficiency anemia) do not 
demonstrate any patterns resembling the cluster, the comorbidity distribution appears to be random. 
The map of comorbidities among CRC patients show that a large percentage experience a burden of 
two or more comorbidities. 
Conclusion: The results indicate that comorbidities do play a role in the stage of CRC diagnosis, with 
the data showing greater odds of being diagnosed with early-stage cancer for many of the individual 
comorbidities. The space-time analysis found a significant high rate cluster of late-stage CRC, 
however, mapping the distribution of positively associated comorbidities did not demonstrate a 
pattern matching the cluster.  Further research is needed to examine the impact of comorbidities and 
CRC stage at diagnosis. 
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Background and Statement of the problem  
 
Colorectal cancer (CRC), includes any cancer that arises in the colon or rectum, the part of the 
gastrointestinal system making up the large intestines. CRC is sometimes termed colon cancer, bowel 
cancer, or rectal cancer.7  Several decades ago CRC had a low incidence rate, however, it is now the 
third most common type of cancer and the third most common cause of cancer death among men 
and women in the United States.1-3  The American Cancer Society estimates that in 2020 there will be 
147,950 new cases of CRC and 53,200 CRC related death in the U.S..3  
Kentucky ranks number one in per capita cancer incidence and mortality rates.5  The risk of 
developing any cancer increases with age, the same is true for CRC, older adults (50 years and older) 
have the most CRC burden than any age group.3, 10  CRC incidence reported for 2012-2016 in 
Kentucky was the highest in the nation at 49.2 (per 100,000) and mortality for years 2013-2017, 
Kentucky ranked 5th in the nation with a rate of 16.4 (per 100,000).4-6  Eastern Kentucky, part of the 
Appalachia region, makes up about 15% of the population of Kentucky, yet experiences a higher rate 
of mortality and morbidity than the rest of the state.5  The area also has high prevalence rates of lung 
disease, heart disease, and diabetes.5 
While healthcare professional do not know the cause of CRC, there are many known risk 
factors associated with CRC.2  Risk factors for CRC include family history, being over the age of 50, 
African American race, history of polyps, radiation therapy, inherited and inflammatory diseases, and 
lifestyle factors like low physical activity, smoking, alcohol, obesity, and high-fat diets.2, 7 Diabetes has 
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been found to be the most prevalent comorbidity among CRC patients.8, 9  The risk of developing CRC 
in patients with diabetes is estimated to be more than 25% higher than those without diabetes.9  
There are studies addressing 1) the prevalence of CRC screening and comorbidities within 
Appalachian Kentucky and 2) non-adherence to the standard of care as a contributing factor for 
Kentucky’s high mortality rate.11, 12  To date, there is no known study that has compared CRC 
outcomes and comorbidities across Kentucky.  
Purpose of the Study 
 
To address these gaps in the literature, we conducted secondary data analysis on CRC patients 
in Kentucky using data from the Kentucky Cancer Registry (KCR). KCR is a population-based central 
cancer registry that collects data on cancer, treatment, death, and individual demographic data.  
The overarching purpose of the current study is to explore if comorbidities impact CRC 
progression, CRC outcomes, and the development of second primary malignancy among CRC patients 
age 18 and older in Kentucky diagnosed between January 1, 2003 and December 31, 2016.  
There are three specific aims for this study: 
1. Aim 1 was to characterize the patient factors of socio-demographic and comorbidity by stage 
of diagnosis. 
2. Aim 2 was to examine if comorbidity status is associated with mortality and having second 
primary cancers.  
3. Aim 3 was to perform a space-time cluster analysis of late-stage at diagnosis to investigate its 





 Research hypotheses 
H1: CRC patients in Kentucky without comorbidity are more likely to be diagnosed with late-stage 
cancer compared to patients with comorbidity.  
H0: There is no difference in the diagnosis of late-stage CRC patients in Kentucky with or without 
comorbidity. 
H2: CRC patients in Kentucky with comorbidity are more likely to be diagnosed with a second primary 
malignancy compared to patients without comorbidity. 
H0: There is no difference in the diagnosis of second primary malignancy in CRC patients with or 
without comorbidity. 
H3: CRC patients in Kentucky with comorbidity have higher all-cause mortality compared to patients 
without comorbidity. 
H0: There is no difference in all-cause mortality in CRC patients with or without comorbidity. 
H4: CRC patients in Kentucky with comorbidity have higher CRC mortality compared to patients 
without comorbidity. 
H0: There is no difference in CRC mortality in CRC patients with or without comorbidity. 
H5: High rate late-stage CRC diagnoses in Kentucky will be spatially and temporally correlated with 
low rates of CRC morbidity. 
H0: There is no spatial or temporal correlation between high rates of late-stage diagnosis and CRC 
comorbidities among CRC cases in Kentucky.  
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Significance of the study  
This study will add to the extant literature by examining the relationship between comorbidity 
and cancer outcomes including survival and development of second primary malignancy across 
Kentucky to inform comprehensive prevention programs targeting populations identified at risk. The 
results of this study will also be useful for informing future CRC and comorbidity research. 
Limitations and delimitations of the study 
There are several potential methodological limitations that should be considered when 
interpreting data on second primaries when using a population-based cancer registry. One major 
limitation is the lack of a standard definition of multiple primaries that can be applied across all 
diagnosed cases, a person diagnosed in 2003 would have different classification rules from someone 
diagnosed in 2005, 2007, or 2018.13-17  This makes it extremely difficult to be accurate and compare 
multiple primaries across years.17  The data set includes second primary according to the rules during 
the time period of the diagnosis.  The biggest limitation of these data is with regards to changes in the 
rules for diagnosis of second primaries during different time periods. Second primaries would not 
mean the same thing between those time periods and this would affect the interpretation of the 
results.  For the study time period 2003-2016, KCR’s multiple primary rules remained relatively 
similar. Other potential limitations include not all cases being captured, incomplete data due to 
clerical errors, and missing data due to unavailability.18  The missing comorbidities data could be due 
to the reality that many reporting hospitals are not part of the Commission of Cancer (CoC), a group 
that requires comprehensive standardized data collection.19, 20  Another limitation would be patients 
receiving surgery for something other than a malignancy, such as receiving resection of the colon that 




Overview of Project Processes 
 Descriptive statistics were used to compare the socio-demographic and comorbidity factors in 
CRC patients included and excluded from the study. Odds ratios and 95% confidence intervals were 
estimated from Logistic regression. Multivariable Cox proportional hazard regressions were used to 
examine if comorbidity status was associated with CRC survival and second primary malignancy. The 
statistical software SAS version 9.4 was used for all of the above analyses.21   The spatial software, 
SaTScan and ArcGIS, were also used to perform spatial analysis and visualize the prevalence of 
comorbidity among CRC patients in Kentucky.22, 23 
Definition of Terms in context of this study 
• Colorectal Cancer (CRC)- an initial primary cancer that arises in the colon or rectum 
• Comorbidity – a chronic health condition in the presence of primary CRC 
• Multi-morbidity – the presence of two or more comorbidities in the presence of primary CRC 
• Second primary malignancy – an additional primary cancer that arises after the first primary 
cancer has been diagnosed and treated 
• Kentucky Cancer Registry (KCR) – a population-based registry in Kentucky that collects cancer 








The purpose of this literature review is to introduce and orient the topics of interest for this 
CRC study. The goal is to identify any gaps in knowledge surrounding CRC, comorbidities, and the use 
of spatial analysis to view disease distribution over a geographical area.   
Cancer Surveillance 
Cancer surveillance is the routine continuous systematic collection and analysis of data on 
new cancer incidences, morbidity, treatment, survival, and mortality.24, 25  Cancer surveillance 
quantifies the incidence of cancer and its related factors (e.g., genetic or behavioral factors)  in a 
defined population to provide a means by which the observations can be used in research to facilitate 
interventions and reduce the burden of cancer.24, 25  Cancer surveillance, like that of other Public 
Health Surveillance programs have strict inclusion criteria that could include diagnosis, timing, and/or 
be laboratory confirmed to be considered a case, while a clinical diagnosis may not be as involved for 
a patient to receive the diagnosis and treatment.26   
In the United States there is no nationally recognized single surveillance program.25  While 
there are several smaller registries that are created from doctors’ offices, hospital and healthcare 
system registries, to state population-based registries, there are two important national cancer 
surveillance programs, National Program of Cancer Registries (NCPR) and The Surveillance, 
Epidemiology and End Results Program (SEER).25  
In Kentucky, the state cancer registry, Kentucky Cancer Registry (KCR), began as a voluntary 
reporting system until legislation mandated reporting starting in 1991.27  KCR is funded by NPCR and 
SEER. Data collected by KCR is sent to the umbrella organization, North American Association of 
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Central Cancer Registries (NAACR) to be independently evaluated for completeness, accuracy, and 
timeliness.20, 27  Kentucky Cancer registry is very thorough, and among the most accurate and 
complete population-based registries.27 
Colorectal Cancer 
CRC, includes any cancer that initiates in the colon or rectum, the portion of the 
gastrointestinal system that makes up the majority of the large intestines, other names for CRC are 
colon cancer, bowel cancer, or rectal cancer.7  The anus is the final part of the large intestine but 
because of the cell types are different that make up the anus, any cancers originating in the anus is 
classified as anal cancer.3  The colon is made up of four sections, the ascending colon, transverse 
colon, descending colon, and the sigmoid colon, it is about 5 feet long and is connected at the bottom 
to the rectum.3  There are three functions of the large intestine including absorption of electrolytes 
and water from food being digested, production and absorption of vitamins, and the formation and 
elimination of fecal waste from the body.3, 28 
CRC is ranked third for most commonly diagnosed cancer and it is also the third leading cause 
of cancer death in both men and women.3  While there are no certain causes of CRC, there are many 
known risk factors.2  Risk factors for CRC include advanced age, African American race, history of 
polyps, family history of colon cancer, sedentary lifestyle, high-fat diet, diabetes, obesity, smoking, 
radiation therapy, alcohol, and inherited and inflammatory diseases.2, 7 
Patient Factors 
Age  
The median age at diagnosis for rectal cancer is 63 years old and median age of diagnosis for 
colon cancer is 68 in men and 72 in women.29  The majority of CRCs are diagnosed in people over the 
age of 50, with only around 12% being diagnosed in people under the age of 50.3  The incidence of 
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CRC in patients under the age of 50 has been increasing, however healthcare providers are not sure 
the reason behind the increase.2, 10  One author found that patients diagnosed at younger than 50 
years of age presented with advance stage and higher recurrence of CRC than older patients but the 
two groups had comparable survival.10  Right-sided colon cancer seems to be more prevalent in older 
adults and women and this type of CRC usually presents at more advanced stages with lower survival 
rate.30 
Sex 
The lifetime risk of developing cancer is similar in both men and women, about 1 in 23 men 
and 1 in 25 women, a difference of 0.3% incidence.7  Socioeconomic factors seem to 
disproportionately affect CRC incidence rates in men. One study from England found that the most 
deprived areas had a 13% higher incidence rate compared to the least deprived areas; there was no 
difference found in women.31  The author also noted that men are less aware of cancer signs and 
symptoms compared to women.31  Another study noted that genetic and environmental factors are 
believed to play a role in sex-associated differences in CRC, with high-fat diet being associated with 
the risk and development on CRC.32  The biological responses to diet are different among men and 
women.32  Studies have associated women with a higher proportion of right-sided colon cancer, 
which usually presents at a more advanced stage, which might account for women having a lower 5-
year survival rate.30, 32  
Second Primary 
A second primary is a new primary cancer that arises in a person that has had a diagnosis and 
treatment for a  non-related cancer in the past.33  Second primaries comprise almost 19% of incident 
cancer cases.34  Patients can have multiple primaries, the requested data included the number of 
primary cancers, including the first primary cancer of CRC. Patients that have had CRC often have 
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several health problems, including a higher risk of secondary cancers.34, 35  People that have had colon 
or rectal cancers can develop any second primary cancer but are at an increased risk of developing 
colon, rectal, stomach, small intestine, anal, or lung cancer.35, 36  While the risk of secondary primary 
cancers is complex, genetics, previous cancer treatments, and environmental exposures have been 
recognized as risks to developing a second primary.34, 37  
Comorbidities 
Elixhauser groups 
A comorbidity is defined as a disease or condition that exists simultaneously with another 
index condition of interest.38, 39  The presence of comorbidity in addition to an index condition such as 
cancer has become increasingly more common with much evidence supporting the majority of the 
comorbidity burden is concentrated in patients that are older, those in minority groups, and those 
patients living in poverty-stricken areas.39   The presence of comorbidities varies by cancer site and is 
difficult to determine an accurate prevalence.38, 39  Comorbidity is usually assessed as a contributor to 
a health outcome, like cancer survival, using methods such as individual disease indexes or counts 
and weighted grouped variables to help describe overall disease burden and health status of a 
patient.38, 40   
 In this study, comorbidities will be looked at both on an individual level and an index, using 
the Elixhauser comorbidity index. The Elixhauser comorbidity index includes 29 individual comorbid 
conditions that were initially selected and refined by examining the literature.41-43  The final use of 
the Elixhauser index was modified to only include 26 groupings. Diabetes with and without chronic 
complications was combined into one group. Three of the groupings, metastatic cancer, lymphoma, 
and solid tumor without metastasis were not evaluated. Although the Kentucky Cancer Registry 
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captures these data, these cancers should not be considered comorbid conditions as part of the index 
since the disease of interest is also cancer.  
Prior to the newest Elixhauser measure, there were 31 groupings, the updated version has 
since collapsed hypertension (complicated and uncomplicated) and removed cardiac arrhythmias, as 
research has shown cardiac arrhythmia was not a good indicator of readmission, and questions 
remain around its reliability as a comorbidity.41, 44   The older Elixhauser measure that used ICD-9-CM 
diagnosis codes was converted to the new Elixhauser version, which utilized ICD-10-CM codes, and 
combined according to Agency for Healthcare Research and Quality’s (AHRQ) guidelines.41, 45   
Traditionally the Elixhauser index has been used in research as a count index, more eligible diagnoses 
would lead to a higher count and risk to the patient.46-48   This index, like the Charlson Comorbidity 
index, has been used to predict in-hospital mortality, high-risk patients, and scenarios that may need 
a higher intervention of care both while in the hospital and when transitioning out of the hospital to 
prevent readmissions.44, 45, 49   One study found that using the individual Elixhauser comorbidities in a 
regression gave slightly better results compared to the Elixhauser index score and it is possible “that a 
comorbidity measure with more variables can lose more information than one with a smaller number 
of variables in finite sample sizes”.48   While the index score is important to use, the objective of this 
study is not focused on hospital utilization and readmission; the individual and grouped comorbid 
conditions are more important to use in this study.  
Colorectal cancer and comorbidities 
A number of studies have shown that cancer patients with comorbidity have lower survival 
compared to cancer patients without comorbidity.50   Although the pattern of comorbidities and their 
risk factors among CRC patients is not well documented globally, there is however, consistent 
evidence illustrating the effect of comorbidities on CRC outcomes.8   Morbidities are often associated 
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with the elderly, but have recently been occurring in younger patients living in socioeconomically 
deprived areas.51   A study of adults with hypertension found that in a year of visits with their primary 
care provider, only one third were related to hypertension while the next most common reason for 
their care visit was for diabetes.51   Studies have found that morbidities, both physical and mental 
health conditions, do not exist in isolation and are influenced by an individuals’ society and family.8, 51 
Studies have found that diabetes is the most prevalent comorbidity among CRC patients.8, 9   The risk 
of CRC in patients with diabetes is estimated to be more than 25% higher than those without 
diabetes.9  
Another study found that CRC patients can be grouped into four classes based on defined 
clusters of comorbid conditions.40   Class one represented the largest part of the sample and included 
patients with no Charlson-defined comorbidities or only one morbidity.40   Classes two and three 
were similar in size and age at diagnosis, however class two patients comorbid conditions were 
primarily characterized as cardiovascular or cardiorespiratory diseases, while class three comorbid 
conditions were primarily diabetes with complications such as kidney disease.40   Class four consisted 
of less than 8% of the study population and were comprised of the patients with the presence of four 
or more comorbidities.40   Class one patients had the highest survival probability followed by class 
three, class two, and then class four, with the lowest survival probability -- 43% lower than class 
one.40   The majority of class four patients were older with a higher burden of comorbidity.40   Despite 
the increasing importance of comorbidity among cancer patients, many challenges and questions 
remain.50  Cancer patients with comorbidities have compromised treatment plans, effectiveness, and 
compliance, and we do not know the duration and severity of the influence of comorbidity on cancer 






The Appalachian region includes all of West Virginia and parts of 12 other states, including 54 
counties in the southeastern and eastern area of Kentucky.53, 54   Within the Appalachian region, and 
more specifically rural Appalachia, health disparities have been well documented.53   Appalachia as a 
whole experiences higher rates of mortality and chronic diseases such as diabetes, chronic 
obstructive pulmonary disease, heart disease, stroke, and cancers such as lung, breast, and CRCs than 
non-Appalachian areas.53-55   Health disparities and disease in Appalachia are exacerbated by 
socioeconomic, behavioral, and geographical factors such as environmental exposures, poverty, low 
literacy rates, lack of health insurance coverage, long distances from home to clinics and healthcare 
providers, high rates of obesity and smoking, low physical activity, and many other multifactorial 
issues.53, 55   Appalachia has high rates of CRC incidence and mortality and CRC is one of the leading 
causes of cancer deaths in Appalachia in both men and women.56, 57  
 
Interaction of patient factors and geospatial data 
Geographic information systems (GIS) are used in epidemiological research to identify the 
“where” of disease.58   Spatial data in public health studies allows for researchers to visualize disease 
and patient attributes across geographic areas which can help to identify and characterize health 
trends over time.59, 60   Spatial analysis of patient data can help to determine clustering or patterns in 
geographic areas that will help to understand patient populations at higher risk, determine any 
socioeconomic factors, and highlight areas that would need intervention in addressing health 
disparities.59, 60   Cluster analysis is useful in producing estimates where limited data is available and 
providing statistical evidence of diseases.58   Creating maps based on disease information more easily 
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reveals geographic-related information about disease distribution than typical research tables 
showing data.58 
Utilizing SaTScan in this study to perform a cluster analysis was helpful in detecting areas with 
high or low rates of statistical significance during time period, 2003-2016.22   SaTScan was required to 
perform the analysis because it is not available in standard GIS software packages.61   For mapping 
purposes, the resulting cluster analysis from SaTScan was exported and layered with a map of 
Kentucky in ArcGIS 10.7.1.62   ArcGIS was also used to map the proportion of comorbidities and late-
stage cancers within each county.23   These maps are necessary for us to visualize the geographic 



















Paper 1: The Effect of Comorbidities on Colorectal Cancer Stage at Diagnosis, 





Colorectal cancer (CRC) is cancer that begins in the colon or rectum, the portion making up 
the large intestines of the gastrointestinal system, other names are colon cancer, bowel cancer, or 
rectal cancer.7   CRC is the third most common type of cancer and the third most common cause of 
cancer death among men and women in the United States.1-3   By 2020, The American Cancer Society 
estimates that there will be 147,950 new cases of CRC and 53,200 CRC related death in the U.S..3 
Kentucky ranks number one in overall cancer per capita incidence and mortality rates.5 Kentucky had 
the highest CRC incidence in nation with 49.2 (per 100,000) for years 2012-2016 and ranked 5th in the 
nation in CRC mortality at a rate of 16.4 (per 100,000) for years 2013-2017.3-6 
  Eastern Kentucky, consisting of much of Kentucky’s Appalachia region, is estimated to 
include slightly under 15% of the population of the state, yet the poverty-stricken area experiences a 
higher rate of mortality and morbidity than the rest of the state and the nation.5   The area is also 
known for its high prevalence rates of chronic illnesses such as lung disease, heart disease, and 
diabetes.5 
A comorbidity is defined as a chronic illness that exists concurrently with an index condition of 
interest.38, 39   In this study, the index condition is primary CRC. The presence of comorbidity in 
addition to an index condition, like CRC has become increasingly more common with considerable 
evidence supporting a larger part of the burden is concentrated in older patients, minority groups, 
and patients living in poverty-stricken or deprivation areas.39   
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The presence of comorbidity can vary by cancer site making it difficult to determine an 
accurate prevalence.38, 39   In this study, comorbidities will be examined on an individual level as well 
as aggregated into groups, using the Elixhauser comorbidity index. The Elixhauser comorbidity index 
includes 29 individual comorbid conditions, that were grouped according to similar body systems (i.e. 
grouping acute heart failure with chronic heart failure in the congestive heart failure group) reference 
table 1-1.41, 42   Comorbidity is usually assessed as a contributor to health outcomes, like cancer 
survival, using methods such as individual disease indexes or scores and weighted grouped variables 
to help describe a patient’s overall disease burden and health status.38, 40   As such, the Elixhauser 
index was chosen for use in the current study.  
The exact cause of CRC is not known, however there are many known risk factors associated 
with CRC.2   The risk associated with developing any cancer increases with age, the same is true for 
CRC, older adults (50 years and older) have the most CRC burden than any age group.3, 10   Other 
known risk factors for CRC include family history of CRC, being of African American race, history of 
polyps, history of radiation therapy, other inherited and inflammatory diseases, and lifestyle factors 
like low physical activity, smoking, alcohol, obesity, and high-fat diets.2, 7   Diabetes has been found to 
be the most prevalent comorbidity among CRC patients.8, 9   The risk of developing CRC in patients 
with diabetes is estimated to be more than 25% higher than those without diabetes.9  
The purpose of this study is to explore if comorbidities impact CRC progression, CRC 
outcomes, and the diagnosis with a second primary malignancy among CRC patients aged 18 and 
older in Kentucky diagnosed between January 1, 2003 and December 31, 2016. There are two specific 
aims for this study. Aim 1 was to characterize patient factors of socio-demographic and comorbidity 
by stage of diagnosis. Aim 2 was to examine whether comorbidity status is associated with stage at 
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diagnosis, mortality, and the development of second primary cancers. To our knowledge, this will be 
the first study that has compared CRC outcomes and comorbidities across Kentucky.  
Methods 
 
Study Design and Data Source 
This is a retrospective cohort study of CRC cases in Kentucky. We started out with 28,229 
incident cases of first primary CRC diagnosed between January 1, 2003 and December 31, 2016 and 
excluded a combined total of 7,658 cases due to missing information. The excluded cases included 
6,054 because of missing morbidity information and 2,730 (1,126 of these were also missing 
morbidity information and included in the above number) because of missing stage. The final study 
population included 20,571 CRC cases. Table 1-2 compares included and excluded cases.  All cases 
were identified from the Kentucky Cancer Registry (KCR). KCR is funded in part by Surveillance, 
Epidemiology, and End Results Program (SEER) and National Program of Cancer Registries (NCPR), 
and North American Association of Central Cancer Registries (NAACR).20, 27   KCR data is sent to the 
umbrella organization, North American Association of Central Cancer Registries (NAACR) to be 
independently evaluated for completeness, accuracy, and timeliness.  Approval for this study was 
granted by the University of Kentucky Internal Review Board. 
 
Variables 
Sex, age at diagnosis, race, ethnicity, marital status at diagnosis, number of primaries, survival 
for primary and a subsequent second primary, Appalachian status, vital status, primary payer, best 
stage group, treatment composite, comorbidity (up to 10 independent variables of ICD-9-CM 
diagnosis codes), and secondary diagnosis (up to 10 independent variables of ICD-10-CM diagnosis 
codes) were provided by KCR.  Age at diagnosis was categorized into five age groups, 18 - 34, 35 - 44, 
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45 – 54, 55 – 64, and 65+ years. Number of primaries was coded as 0 for the initial CRC primary of 
interest and 1 for any patient that had been diagnosed for any subsequent primaries not related to 
their initial primary of CRC. Race was categorized as white, black, and other. Ethnicity was categorized 
as non-Hispanic or Hispanic. Marital status at diagnosis was categorized at married, single, or other. 
Primary payer was categorized as Medicaid, Medicare, military/other, private pay, and not insured. 
The variable treatment had 15 combinations of treatment, including no treatment, and variations of 
surgery, radiation therapy, chemotherapy, and other therapies. The other therapies were not 
expressly specified, but typically include immunotherapy. Treatment coding in this study was based 
on the available dataset and a CRC study by Rane et al.63 The final coding included six classes: no 
treatment, surgery at primary site only, chemotherapy only, radiation only, chemotherapy and 
radiation, and surgery at primary site and chemotherapy/or radiation.                     
Comorbidity was measured using the diagnosis codes from the variables comorbidity and 
secondary diagnosis and entering into the Elixhauser Comorbidity Software, Version 3.7 for ICD-9-CM 
and the Elixhauser Comorbidity Software for ICD-10-CM from Healthcare Cost and Utilization Project 
by the Agency for Healthcare Research and Quality.41, 45   The software classifies certain diagnoses 
codes as part of the Elixhauser Comorbidity index, outputting individual variables for the 31 (Version 
3.7)/29 Elixhauser groups. The final variables were combined to match the most up-to-date 
Elixhauser index, removing arrhythmias and combining hypertension.41   Elixhauser groups related to 
cancer, solid tumors without metastases, metastatic cancer, and lymphoma were removed. Cancer is 
the outcome of interest, and therefore it cannot be a comorbidity. Diabetes with and without chronic 
complications were combined after observing some patients had both diagnosis codes.  
The Adult Comorbidity Evaluation-27 (ACE-27) index morbidity groupings were considered, 
however, available data only includes diagnosis codes, indicating the presence of disease but not 
18 
 
disease severity.64   ACE-27 grades the extent of organ decompensation on three grades of severity, 
mild, moderate, and severe, data from KCR did not allow for measurement of such 
decompensation.65   Nonetheless, studies have also shown that the Elixhauser measure performs 
better than other comorbidity indexes.46, 48, 49, 66   Table 1-1 shows the morbidity mapping from ACE-
27 and Elixhauser Comorbidity index to the final inclusion of comorbidities (individual and grouped).   
The KCR variables with diagnoses codes include coding for patients with no known morbidities 
(comorbidity diagnosis code of 0000 or a secondary diagnosis entry of 0). Patients with these entries 
in any diagnoses code variables were treated as having no morbidity. Patients with diagnosis code(s) 
in the comorbidity/secondary diagnosis variables that are not part of the Elixhauser groups were also 
treated as having no morbidity. Cases with unknown morbidity status and unknown stage at 





All analyses were carried out with SAS 9.4 statistical software.21   Included and excluded 
patients were compared on demographic and disease characteristics using column percentages to 
observe comparisons between groups (see Table 1-2).  Included patient demographic characteristics 
stratified by cancer stage, early and late using row percentages as comparison can be found in Table 
1-2b.  
To explore the relationship between morbidities, stage, and survival, a series of bivariate 
models were fitted. Two logistic regression models were fitted (tables 1-3 and 1-4), one with stage at 
diagnosis (late versus early) and the other with vital status (died versus alive). A cancer specific 
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survival model was estimated using Cox proportional hazard regression. Kaplan-Meier survival curves 
for primary CRC survival were also analyzed using SAS 9.4 software and can be found in figure 1-2.21  
Next, a series of multivariable fully adjusted statistical models for estimating the risk of 
mortality or second primary were specified. These models were Cox proportional hazard models that 
were fitted to explore the relationship between patient factors and morbidities on survival and 
second primary malignancy. The first set of three Cox proportional hazard models looked as all-cause 
mortality and can be found in table 1-6. The second set of three Cox proportional hazard models 
looked as CRC-cause mortality and can be found in table 1-7. The third set of three Cox proportional 
hazard models looked at second primary cancer and can be found in table 1-8. The three sets of 
models included sociodemographic data, cancer stage, and followed different categories of 
Elixhauser comorbidities; Model 1 used the individual Elixhauser morbidities, Model 2 used Elixhauser 
grouped comorbidities based on Table 1-1, and then Model 3 used a total count of the number of 




Table 1-1. Morbidity Mapping ACE-27 Index, Elixhauser, and Final Inclusion Study Comorbidity and 
Groupings  
Ace-27 Index  Elixhauser  ICD 10* Final Inclusion 
Cardiovascular System 
Myocardial Infarct  
Angina / Coronary Artery Disease 




Peripheral Arterial Disease 
Respiratory System 
Restrictive Lung Disease or COPD  
Other markers not diagnoses 
Gastrointestinal System 
Hepatic 
Stomach / Intestine 
Pancreas 
Renal System 
End-stage renal disease 








Recent suicidal attempt 
Schizophrenia 




Mixed Connective Tissue Disorder 
Polymyositis  
Rheumatic Polymyositis 
Immunological System  
AIDS 
Malignancy  
Solid Tumor including melanoma 
Leukemia and Myeloma 
Lymphoma  
Substance Abuse  
Alcohol 
Illicit Drugs  
Body Weight 
Obesity 
Congestive Heart Failure 
Valvular disease 
Pulmonary circulation disorders 
Peripheral vascular disease 
Hypertension (Complicated & 
Uncomplicated) 
Paralysis 
Other neurological disorders 






Chronic peptic ulcer disease 
HIV and AIDS  
Lymphoma 
Metastatic cancer 
Solid tumor without metastasis 





Fluid and electrolyte disorders 














Congestive Heart Failure 
Hypertension  
Peripheral Vascular Disorder 
Valvular Heart Disease 
Respiratory System  
Pulmonary Circulation Disorders 
Chronic Pulmonary 
Gastrointestinal System  
Liver Diseases 
Peptic Ulcer Disease  
Renal System  
Renal Failure 
Endocrine System  
Diabetes (Complicated & Uncomplicated)  
Hypothyroidism 
Neurological System  
Paralysis 






Immunological System  
AIDS/HIV 
Substance Abuse  
Alcohol Abuse 
Drug Abuse 
Body weight  
Obesity 
Blood System  
Coagulopathy 
Blood Loss Anemia 
Deficiency Anemia 
Remain but not grouped 
Weightloss 
Fluid & Electrolyte Disorders 
*Elixhauser ICD-9 (31 Variables) conversion to ICD-10 (29 Variables) version changes: Removal of Cardiac Arrhythmia and 
Combining of Hypertension with and without complications. Some data were collected prior to the 2015 ICD-10 activation, 



































Age    
18 - 34 years 
35 - 44 years 
45 - 54 years 
55 - 64 years 
































































































































































































































Appalachian 3,045(26.74%) 2,593(28.23%)   5638(27.41%) 2,708(44.73%) 855 (31.32%) 3162(41.29%) p <0.001 
Diabetes 2169 (19.05%) 1653 (18.00%) 3822 (18.58%) - 198 (7.25%) 198(2.59%) p <0.001 
Renal Failure 412 (3.62%) 290 (3.16%) 702 (3.41%) - 43 (1.58%) 43 (0.56%) p <0.001 
Liver Disease 287 (2.52%) 328 (3.57%) 615 (2.99%) - 32 (1.17%) 32 (0.42%) p <0.001 
CHF 834 (7.32%) 601 (6.54%) 1435 (6.98%) - 133 (4.87%) 133 (1.74%) p <0.001 










































































































































































































2003 – 2009 











































































































Table 1-3. Patient Demographics (Percentage based on rows) 
Demographics Early Stage (0-II) N=11387 Percent 
Late Stage (III – IV) 
N=9184 Percent 
Age    
18 - 34 years 
35 - 44 years 
45 - 54 years 
55 - 64 years 




























































































































Appalachian 3,045 54.01% 2,593 45.99% 
Diabetes 2,169 56.75% 1,653 43.25% 
Renal Failure 412 58.69% 290 41.31% 
Liver Disease 287 46.67% 328 53.33% 
CHF 834 58.12% 601 41.88% 
Hypertension 5,384 57.05% 4,053 42.95% 























































Number of Primaries 
1 


















































Year of diagnosis 
2003 – 2009 



















More than 5 years  



































The demographic, clinical, and survival characteristics stratified by stage for included and 
excluded subjects is presented in Table 1-2. The main differences between the included and excluded 
cases were that the excluded cases had a higher percentage of patients from the Appalachian region 
(41.29% compared to 27.41%) and excluded cases had a higher percentage of cases in the 0-12 
month survival interval (34.15% compared 23.01%). The remaining variables were similar, except for 
the morbidity variables, having 79.05% of the excluded cases missing morbidity status, comparison 
would not be recommended. For those only missing stage, the individual morbidity groups were at 
least 40% lowers in all categories, CHF, diabetes, hypertension, renal failure, and liver disease 
compared to the included cases.  
The demographic, clinical, and survival characteristics stratified by stage for included subjects 
only is summarized in Table 1-3.  Early-stage CRC makes up 55.4% of the total and the remaining 
44.6% were late-stage cases. Comparing the demographic distribution of CRC range differences 
within 10% of expected distribution will not be noted. Late-stage CRC patients had a higher 
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percentage of younger patients (age groups 18-34 and 35-44 years), Hispanic patients, death, liver 
disease, higher percentage of patients surviving less than 24 months, and higher percentage primary 
payer sources of Medicaid, Military/other, and uninsured. Late-stage patients tended to have a lower 
percentage of second primary malignancies, primary survival beyond 48 months, and secondary 
survival beyond 12 months.    
Bivariate models using the Elixhauser index predicting late-stage cancer by individual and 
grouped comorbidities are in Table 1-4. Individual comorbidities found to be statistically significant 
were CHF, hypertension, chronic pulmonary disease, liver disease, hypothyroidism, coagulopathy, 
blood loss anemia, deficiency anemia, depression, weight loss, and electrolyte disorders.  Some 
comorbidities increased the odds of late-stage disease, e.g. liver disease (OR=1.432, 96% CI = 1.220 – 
1.682), while others decreased the odds, e.g., hypertension (OR= 0.881, 95% CI = 0.883 – 0.931). 
Grouped comorbidities found to be statistically significant were cardiovascular system, respiratory 
system, gastrointestinal system, endocrine system, blood system, and having two or more individual 
comorbidities. Bivariate models predicting death by individual and grouped comorbidities are in Table 
1-5. All but five individual comorbidities (excluding hypertension, peptic ulcer disease, 
hypothyroidism, drug abuse, and depression) and all but one comorbidity group (psychiatric) were 
found to be statistically significant below the alpha level of 0.05 and the corresponding 95% 
confidence limits did not include one. 
There were three sets of three Cox proportional hazard models fitted, for a total of nine 
models. These models were progressive comparisons of comorbidities from an individual level, to a 
grouped body system level, and then an aggregate count of comorbidities. Some variables from the 
individual level were not able to be grouped with other individual comorbidities and were therefore 
transferred into the grouped model as their own group. 
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Cox proportional hazard models of all-cause mortality can be found in Table 1-6 and includes 
20,270 CRC patients from Kentucky diagnosed 2003-2016; there are three models viewing 
comorbidity through an individual, system, or aggregate count lens.  
Model 1 includes Individual comorbidities and patient factors. Due to the large number of 
significant findings, we will group the statistically significant results in order from largest to smallest 
effect. The individual comorbidities and patient factors that increased the hazard of all-cause 
mortality by greater than 40% that were found to be significant were late-stage (HR= 3.198, 95%CI 
3.046-3.357), aids (HR= 2.901, 95% CI 1.926-4.373), being 65 years or older (HR= 1.746, 95%CI 1.421-
2.143), primary payer sources of uninsured (HR= 1.711, 95%CI 1.538-1.903) or Medicaid (HR= 1.617, 
95% CI 1.481-1.767), renal failure (HR= 1.570, 95%CI 1.432-1.720), CHF (HR=1.566, 95%CI 1.467-
1.672), weight loss (HR= 1.540, 95%CI 1.427-1.662 ), other neurological disorders excluding paralysis 
(HR= 1.487, 95%CI 1.358-1.627), and coagulopathy (HR= 1.426, 95%CI 1.213-1.676 ). The individual 
comorbidities and patient factors that increased the hazard of all-cause mortality by greater than 20% 
but less than 40% that were found to be significant were pulmonary circulation disorders (HR= 1.394, 
95%CI 1.204-1.615), electrolyte disorders (HR= 1.353, 95%CI 1.280-1.430 ), paralysis (HR= 1.347, 
95%CI 1.087-1.671 ), primary payer source of Medicare (HR= 1.338, 95%CI 1.249-1.434 ) and 
Military/other (HR= 1.317, 95%CI 1.076-1.612 ), chronic obstructive pulmonary disorder (HR= 1.290, 
95%CI 1.224-1.359), liver disease (HR= 1.226, 95%CI 1.105-1.360), rheumatoid arthritis (HR= 1.223, 
95%CI 1.023-1.462), and alcohol abuse (HR= 1.202, 95%CI 1.031-1.401). The individual comorbidities 
and patient factors that increased the hazard of all-cause mortality by up to 20% that were found to 
be significant were peripheral vascular disease (HR= 1.157, 95%CI 1.044-1.281), deficiency anemia 
(HR= 1.146, 95%CI 1.086-1.210), being African American race (HR= 1.131, 95%CI 1.050-1.219), 
Appalachian (HR= 1.112, 95%CI 1.064-1.163), being male (HR= 1.074, 95%CI 1.032-1.118), and having 
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diabetes (HR= 1.068, 95%CI 1.015-1.123). The individual comorbidities and patient factors that were 
protective and decreased the hazard of all-cause mortality by up to 20% were hypertension (HR= 
0.929, 95%CI 0.892-0.968), having a second primary malignancy (HR= 0.928, 95%CI 0.879-0.980), 
obesity (HR= 0.891, 95%CI 0.808-0.984), and blood loss anemia (HR= 0.872, 95%CI 0.788-0.964). The 
individual comorbidities and patient factors that were protective and decreased the hazard of all-
cause mortality between 20% but less than 40% were being an other race compared to white (HR= 
0.698, 95%CI 0.496-0.983) and receiving radiation therapy only (HR= 0.694, 95%CI 0.551-0.874). The 
individual comorbidities and patient factors that were protective and decreased the hazard of all-
cause mortality by more than 40% were all treatments, in order of least to greatest, chemotherapy 
only (HR= 0.520, 95%CI 0.467-0.580), chemotherapy and radiation (HR= 0.362, 95%CI 0.318-0.411), 
surgery on the primary site only (HR= 0.183, 95%CI 0.169-0.198), and the largest reduction in hazards 
with the treatment combination of surgery with radiation and/or chemotherapy (HR= 0.118, 95%CI 
0.108-0.128).   
Model 2 includes grouped comorbidities and patient factors. Again, due to the large number 
of significant findings, statistically significant results will be grouped in order from largest to smallest 
effect. The individual comorbidities and patient factors that increased the hazard of all-cause 
mortality by greater than 40% that were found to be significant were late-stage (HR= 3.211, 95%CI ), 
aids(HR= 3.083, 95%CI 2.046-4.645), being 65 or older (HR= 1.743, 95%CI 1.420-2.140), being 
uninsured (HR= 1.728, 95%CI 1.554-1.921), having renal failure (HR= 1.685, 95%CI 1.539-1.845), 
having Medicaid insurance (HR= 1.619, 95%CI 1.482-1.768), weight loss (HR= 1.542, 95%CI 1.429-
1.664), and other neurological disease excluding paralysis (HR= 1.536, 95%CI 1.411-1.672). The 
individual comorbidities and patient factors that increased the hazard of all-cause mortality by 
greater than 20% but less than 40% that were found to be significant were electrolyte disorders (HR= 
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1.389, 95%CI 1.315-1.468), respiratory system disorders (HR= 1.373, 95%CI 1.306-1.444), having 
Medicare (HR= 1.341, 95%CI 1.251-1.436) Military/other insurance (HR= 1.337, 95%CI 1.093-1.636), 
and a substance abuse (HR= 1.202, 95%CI 1.050-1.376). The individual comorbidities and patient 
factors that increased the hazard of all-cause mortality by up to 20% that were found to be significant 
were gastrointestinal system disorders (HR= 1.160, 95%CI 1.1.057-1.274), blood system disorders 
(HR= 1.139, 95%CI 1.086-1.195), being of black race (HR= 1.123, 95%CI 1.042-1.210), Appalachian 
(HR= 1.100, 95%CI 1.052-1.150), and being male (HR= 1.083, 95%CI 1.041-1.126). The individual 
comorbidities and patient factors that were protective and decreased the hazard of all-cause 
mortality 20% were secondary primary malignancy (HR= 0.921, 95%CI 0.873-0.972), psychiatric 
disorders (HR= 0.915, 95%CI 0.939-0.998), and obesity (HR= 0.896, 95%CI 0.812-0.989). The individual 
comorbidities and patient factors that were protective and decreased the hazard of all-cause 
mortality between 20% but less than 40% were treatment of radiation only (HR= 0.696, 95%CI 0.553-
0.877) and being an other race compared to white (HR= 0.681, 95%CI 0.483-0.959). The individual 
comorbidities and patient factors that were protective and decreased the hazard of all-cause 
mortality by more than 40% were all treatments, in order of least to greatest, chemotherapy only 
(HR= 0.513, 95%CI 0.460-0.571), chemotherapy and radiation (HR= 0.354, 95%CI 0.312-0.402), 
surgery on the primary site only (HR= 0.183, 95%CI 0.169-0.198), and the largest reduction in hazards 
with the treatment combination of surgery with radiation and/or chemotherapy (HR= 0.114, 95%CI 
0.105-0.124).   
Model 3 includes aggregate count of comorbidities and patient factors. Like the previous 
models, statistically significant results will be grouped in order from largest to smallest effect. The 
individual comorbidities and patient factors that increased the hazard of all-cause mortality by 
greater than 40% that were found to be significant were late-stage (HR= 3.271, 95%CI 3.116-3.434), 
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being uninsured (HR= 1.773, 95%CI 1.595-1.970), having Medicaid (HR= 1.694, 95%CI 1.552-1.846), 
being over the age of 65 (HR= 1.586, 95%CI 1.294-1.943), and having two or more comorbidities (HR= 
1.495, 95%CI 1.421-1.572). The individual patient factor that increased the hazard of all-cause 
mortality by greater than 20% but less than 40% that were found to be significant were having a 
primary payer source of Medicare (HR= 1.388, 95%CI 1.296-1.486) and Military/other (HR= 1.286, 
95%CI 1.051-1.573). The individual comorbidities and patient factors that increased the hazard of all-
cause mortality by up to 20% that were found to be significant were being black compared to white 
(HR= 1.134, 95%CI 1.053-1.222), having one comorbidity (HR= 1.108, 95%CI 1.047-1.173), being male 
(HR= 1.099, 95%CI 1.058-1.143), and Appalachian (HR= 1.052, 95%CI 1.007-1.099). The factor that 
was protective and decreased the hazard of all-cause mortality 20% were having a secondary primary 
malignancy (HR= 0.930, 95%CI 0.881-0.981). The individual patient factors that were protective and 
decreased the hazard of all-cause mortality between 20% but less than 40% were treatment of 
radiation only (HR= 0.738, 95%CI 0.587-0.929) and being of an other race compared to white (HR= 
0.631, 95%CI 0.448-0.889). The individual comorbidities and patient factors that were protective and 
decreased the hazard of all-cause mortality by more than 40% were again all treatments, in the same 
order, chemotherapy only (HR= 0.486, 95%CI 0.436-0.541), chemotherapy and radiation (HR= 0.322, 
95%CI 0.284-0.365), surgery on the primary site only (HR= 0.173, 95%CI 0.160-0.187), and the largest 
reduction in hazards with the treatment combination of surgery with radiation and/or chemotherapy 
(HR= 0.106, 95%CI 0.098-0.115).   
Cox proportional hazard models of CRC mortality can be found in Table 1-7 and includes 9,866 
CRC patients from Kentucky diagnosed 2003-2016, there are three models viewing comorbidity 
through an individual, system, or aggregate count lens.  
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Model 1 includes Individual comorbidities and patient factors. The individual comorbidities 
and patient factors that increased the hazard of CRC mortality were renal failure (HR= 1.809, 95% CI 
1.597-2.05), pulmonary circulation disorders (HR= 1.419, 95% CI 1.148-1.755), CHF (HR= 1.390, 95% CI 
1.27-1.521), weight loss (HR= 1.327,95% CI 1.159-1.519),    other neurological diseases excluding 
paralysis (HR=1.308, 95% CI 1.148-1.49), Medicaid (HR=1.300, 95% CI 1.106-1.529), coagulopathy 
(HR= 1.300, 95% CI 1.02-1.655), chronic obstructive pulmonary disorder (HR= 1.225, 95% CI 1.136-
1.321), Medicare (HR= 1.215, 95% CI 1.087-1.357), electrolyte disorders (HR= 1.182, 95% CI 1.085-
1.288), being male (HR= 1.120, 95% CI 1.052-1.193), deficiency anemia (HR= 1.099, 95% CI 1.01-
1.196), and diabetes (HR= 1.097, 95% CI 1.017-1.184). The individual comorbidities and patient 
factors that were protective and decreased the hazard of CRC-specific mortality were having a second 
primary malignancy (HR= 0.867,  95% CI 0.805-0.933), blood loss anemia (HR= 0.807,  95% CI 0.694-
0.938), treatment of radiation only (HR= 0.488, 95% CI 0.294-0.81), chemotherapy and radiation (HR= 
0.367, 95% CI 0.285 - 0.473) surgery on primary site only (HR= 0.340, 95% CI 0.296-0.39), 
chemotherapy only (HR= 0.242, 95% CI 0.184-0.318), and surgery with radiation and/or 
chemotherapy (HR= 0.179, 95% CI 0.154-0.207).   
Model 2 includes grouped comorbidities and patient factors. The individual comorbidities and 
patient factors that increased the hazard of CRC mortality were renal failure (HR= 1.949, 95% CI 
1.725-2.204), neurological system (HR= 1.386, 95% CI 1.229-1.563), weight loss (HR= 1.344, 95% CI 
1.174-1.539), having Medicaid (HR= 1.301, 95% CI 1.107-1.529), respiratory system (HR= 1.286, 95% 
CI 1.196-1.383), having Medicare (HR= 1.218, 95% CI 1.091-1.361), electrolyte disorders (HR= 1.199, 
95% CI 1.101-1.305), gastrointestinal system (HR= 1.186, 95% CI 1.019-1.381), being male (HR= 1.115, 
95% CI 1.049-1.187), cardiovascular disease (HR= 1.093, 95% CI 1.024-1.166), and endocrine system 
(HR= 1.088, 95% CI 1.013-1.168). The individual comorbidities and patient factors that were 
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protective and decreased the hazard of CRC-specific mortality were having a secondary primary 
malignancy (HR= 0.868, 95% CI 0.807-0.935), radiation therapy only (HR= 0.483, 95% CI 0.291-0.802), 
chemotherapy and radiation therapies (HR= 0.365, 95% CI 0.283-0.471), surgery on primary site only 
(HR= 0.339, 95% CI 0.296-0.389), chemotherapy only (HR= 0.241, 95% CI 0.183-0.316), and surgery 
with radiation and/or chemotherapy (HR= 0.177, 95% CI 0.152-0.205).   
Model 3 includes an aggregate count of comorbidities and other patient factors. The other 
covariates that increased the hazard of CRC mortality include Medicaid (HR=1.334, 95% CI 1.135-
1.567), Medicare (HR = 1.242, 95% CI 1.112-1.388), and male gender (HR = 1.142, 95% CI 1.075-
1.214). The individual comorbidities and patient factors that were protective and decreased the 
hazard of CRC mortality were having a secondary primary malignancy(HR = 0.855, 95% CI 0.794-0.92), 
radiation therapy only (HR = 0.495, 95% CI 0.298-0.822), chemotherapy and radiation (HR = 0.341, 
95% 0.265-0.439), surgery on primary site only (HR = 0.329, 95% CI 0.287-0.378), chemotherapy only 
(HR = 0.228, 95% CI 0.174-0.300), and surgery with radiation and/or chemotherapy (HR = 0.168, 95% 
CI 0.145-0.195). 
Cox proportional hazard models of second primary malignancy can be found in Table 1-8 and 
includes 2,624 CRC patients from Kentucky diagnosed 2003-2016, there are three models viewing 
comorbidity through an individual, system, or aggregate count lens.  
Model 1 includes Individual comorbidities and patient factors. The individual comorbidities 
and patient factors that increased the hazard of secondary primary malignancy were renal failure 
(HR= 1.856, 95% CI 1.428-2.412), being uninsured (HR= 1.786, 95% CI 1.304-2.445), late-stage (HR= 
1.723, 95% CI 1.512-1.963), CHF (HR= 1.670, 95% CI 1.393-2.002), Medicaid (HR= 1.522, 95% CI 1.143-
2.027), Medicare (HR= 1.427, 95% CI 1.181-1.724), weight loss (HR= 1.319, 95% CI 1.033-1.684), 
deficiency anemia (HR= 1.236, 95% CI 1.072-1.426), chronic obstructive pulmonary disorder (HR= 
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1.235, 95% CI 1.079-1.415), electrolyte disorders (HR= 1.173, 95% CI 1.006-1.369), being male (HR= 
1.159, 95% CI 1.041-1.29), and Appalachian (HR= 1.129, 95% CI 1.001-1.275). The individual 
comorbidities and patient factors that were protective and decreased the hazard of secondary 
primary malignancy were surgery on primary site only (HR= 0.568, 95% CI 0.375-0.859) and surgery 
with radiation and/or chemotherapy (HR= 0.477, 95% CI 0.312-0.728). 
Model 2 includes grouped comorbidities and patient factors. The individual comorbidities and 
patient factors that increased the hazard of secondary primary malignancy were aids (HR= 3.310, 95% 
CI 1.058-10.36), renal failure (HR= 1.976, 95% CI 1.529-2.552), being uninsured (HR= 1.798, 95% CI 
1.314-2.460), late-stage (HR= 1.719, 95% CI 1.508-1.96), substance abuse (HR= 1.543, 95% CI 1.083-
2.198), Medicaid (HR= 1.488, 95% CI 1.118-1.980), Medicare (HR= 1.444, 95% CI 1.195-1.745), weight 
loss (HR= 1.296, 95% CI 1.015-1.654), respiratory system (HR= 1.285, 95% CI 1.127-1.466), electrolyte 
disorders (HR= 1.218, 95% CI 1.046-1.420), blood system (HR= 1.198, 95% CI 1.057-1.358), and being 
male (HR= 1.154, 95% CI 1.039-1.281). The individual comorbidities and patient factors that were 
protective and decreased the hazard of secondary primary malignancy were surgery on primary site 
only (HR= 0.542, 95% CI 0.359-0.819) and surgery with radiation and/or chemotherapy (HR= 0.446, 
95% CI 0.293-0.680). 
Model 3 includes an aggregate count comorbidities and patient factors. The individual 
comorbidities and patient factors that increased the hazard of secondary primary malignancy were 
being uninsured (HR= 1.866, 95% CI 1.367-2.546), late-stage (HR= 1.713, 95% CI 1.504-1.952), 
Medicaid (HR= 1.595, 95% CI 1.205-2.113), Medicare (HR= 1.504, 95% CI 1.247-1.813), having two or 
more comorbidities (HR= 1.400, 95% CI 1.226- 1.599), and being male (HR= 1.175, 95% CI 1.059-
1.303).The individual comorbidities and patient factors that were protective and decreased the 
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hazard of secondary primary malignancy were surgery on primary site only (HR= 0.543, 95% CI 0.361-
0.818) and surgery with radiation and/or chemotherapy (HR= 0.443, 95% CI 0.291-0.673). 
Kaplan Meier Survival Curves (Censoring and LifeTest) that compare early to late-stage 
survival of diagnosed primary CRC cases in Kentucky can be found in Figure 1-2. Early-stage failed 
cases (those that died during the interval) were 4,388 and 61.46% were censored (6,999). Late-stage 
failed cases were 6,174 and 32.77% (3,010) were censored. The rank tests for homogeneity indicate a 
significant difference between survival of late and early-stage initial primary CRC. The p values of the 
log-rank test and Wilcoxon test were both <0.001. The height of the drop in the first 24 months is 
very steep for late-stage below 60% CRC patients compared to early-stage that dropped just below 
90%, there were more late-stage patients at risk of failing. At the end of the time period, early-stage 
survival probability is around 60% and late-stage is at 30%. We do not see a steep drop at the end of 




Table 1-4. Elixhauser and Comorbidity Grouping Bivariate (Outcome Late-stage) 




















0.930 Valvular Disorder 0.864 0.713 1.048 
Peripheral 
Vascular Disease 
0.873 0.740 1.030 
Hypertension 0.881*** 0.833 0.931 
Pulmonary 
Circulation 











0.897** 0.828 0.971 







1.601 Peptic ulcer 1.228 0.897 1.681 











0.971 0.836 1.128 







0.976 Hypothyroid 0.874* 0.774 0.987 







1.471 Blood loss Anemia 1.230** 1.065 1.421 
Deficiency Anemia 1.362*** 1.266 1.464 







1.402 Drug Abuse 0.978 0.649 1.473 







1.330 Depression 1.170* 1.027 1.333 
Renal Failure 0.869 0.745 1.012     
Aids 1.436 0.683 3.019     
Obesity 0.920 0.812 1.043     
Rheumatoid 
Arthritis 
1.037 0.791 1.360     
Weight loss 1.856*** 1.636 2.107     
Electrolyte 1.381*** 1.267 1.504     





















Table 1-5. Elixhauser and Comorbidity Grouping Bivariate (Outcome Death) 
























Valvular Disorder 1.679*** 1.378 2.045 
Peripheral Vascular 
Disease 
1.945*** 1.636 2.312 
Hypertension 1.029 0.974 1.087 







2.058 Chronic Pulmonary 1.874*** 1.728 2.033 







1.801 Peptic ulcer 1.309 0.953 1.800 








3.101 Other Neurological 
Disease 
2.532*** 2.146 2.988 







1.196 Hypothyroid 0.896 0.795 1.011 







1.851 Blood loss Anemia 1.872*** 1.608 2.179 
Deficiency Anemia 1.670*** 1.550 1.799 







2.024 Drug Abuse 1.374 0.908 2.079 







1.090 Depression 0.886 0.778 1.010 
Renal Failure 2.974*** 2.500 3.538     
Aids 4.366** 1.659       11.489     
Obesity 0.636*** 0.560 0.721     
Rheumatoid Arthritis 1.404* 1.067 1.849     
Weight loss 2.867*** 2.489 3.303     
Electrolyte 2.289*** 2.088 2.508     





















Table 1-6. Cox Proportional Hazard models of All-cause mortality, 20,270 CRC patients 2003-2016 
 
Variable 













Cardiovascular Disease    1.033 0.992 1.077    
   CHF 1.566*** 1.467 1.672       
   Valvular Disorder 1.047 0.927 1.183       
   Peripheral Vascular Disease 1.157** 1.044 1.281       
   Hypertension 0.929** 0.892 0.968       
Respiratory System    1.373*** 1.306 1.444    
   Pulmonary Circulation 1.394*** 1.204 1.615       
   Chronic Pulmonary 1.290*** 1.224 1.359       
Gastrointestinal    1.160** 1.057 1.274    
   Liver Disease 1.226** 1.105 1.360       
   Peptic ulcer 0.910 0.739 1.121       
Neurological System    1.536*** 1.411 1.672    
   Paralysis 1.347** 1.087 1.671       
   Other Neurological Disease 1.487*** 1.358 1.627       
Endocrine System    1.019 0.972 1.068    
   Diabetes 1.068* 1.015 1.123       
   Hypothyroid 0.918 0.841 1.002       
Blood System    1.139*** 1.086 1.195    
   Coagulopathy 1.426*** 1.213 1.676       
   Blood loss Anemia 0.872** 0.788 0.964       
   Deficiency Anemia 1.146*** 1.086 1.210       
Substance Abuse    1.202** 1.050 1.376    
   Alcohol Abuse 1.202* 1.031 1.401       
   Drug Abuse 1.067 0.811 1.404       
Psychiatric    0.915** 0.839 0.998    
   Psychosis 1.045 0.875 1.248       
   Depression 0.937 0.852 1.030       
Renal Failure 1.570*** 1.432 1.720 1.685*** 1.539 1.845    
Aids 2.902*** 1.926 4.373 3.083*** 2.046 4.645    
Obesity 0.891* 0.808 0.984 0.896** 0.812 0.989    
Rheumatoid Arthritis 1.223* 1.023 1.462 1.179 0.986 1.409    
Weight loss 1.540*** 1.427 1.662 1.542*** 1.429 1.664    
Electrolyte 1.353*** 1.280 1.430 1.389*** 1.315 1.468    
Total Comorbidity          
  0 (ref)       ref ref ref 
  1       1.108** 1.047 1.173 
  2+       1.495*** 1.421 1.572 
Stage of Cancer (late vs early) 3.198*** 3.046 3.357 3.211*** 3.058 3.371 3.271*** 3.116 3.434 
Second primary(yes/no) 0.928** 0.879 0.980 0.921** 0.873 0.972 0.930** 0.881 0.981 
Sex (Female Ref) 1.074** 1.032 1.118 1.083*** 1.041 1.126 1.099*** 1.058 1.143 
Race (black vs white) 1.131** 1.050 1.219 1.123** 1.042 1.210 1.134** 1.053 1.222 
Race (other vs white) 0.698* 0.496 0.983 0.681** 0.483 0.959 0.631** 0.448 0.889 
Age or age group          
18 – 34 years (ref) ref ref ref ref ref ref ref ref ref 
35 – 44 years 0.975 0.780 1.218 0.977 0.782 1.220 0.905 0.725 1.128 
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45 – 54 years 0.991 0.809 1.216 0.982 0.801 1.204 0.911 0.745 1.115 
55 – 64 years 1.166 0.954 1.425 1.152 0.943 1.408 1.054 0.864 1.286 
65 + years 1.746*** 1.421 2.143 1.743*** 1.420 2.140 1.586*** 1.294 1.943 
Source of payment          
Private Payer (ref) ref ref ref ref ref ref ref ref ref 
Medicaid 1.617*** 1.481 1.767 1.619*** 1.482 1.768 1.694*** 1.552 1.849 
Medicare 1.338*** 1.249 1.434 1.341*** 1.251 1.436 1.388*** 1.296 1.486 
Military/Other 1.317** 1.076 1.612 1.337** 1.093 1.636 1.286* 1.051 1.573 
Uninsured 1.711*** 1.538 1.903 1.728*** 1.554 1.921 1.773*** 1.595 1.970 
Appalachian 1.112*** 1.064 1.163 1.100*** 1.052 1.150 1.052* 1.007 1.099 
Treatment          
No Treatment (ref) ref ref ref ref ref ref ref ref ref 
Chemotherapy Only 0.520*** 0.467 0.580 0.513*** 0.460 0.571 0.486*** 0.436 0.541 
Radiation Only 0.694** 0.551 0.874 0.696** 0.553 0.877 0.738** 0.587 0.929 
Surgery on Primary Site Only 0.183*** 0.169 0.198 0.183*** 0.169 0.198 0.173*** 0.160 0.187 
Chemotherapy and Radiation 0.362*** 0.318 0.411 0.354*** 0.312 0.402 0.322*** 0.284 0.365 
Surgery with Radiation 
and/or Chemotherapy 0.118*** 0.108 0.128 0.114*** 0.105 0.124 0.106*** 0.098 0.115 





Table 1-7. Cox Proportional Hazard models of CRC mortality, 9,866 CRC patients 2003-2016 
 
Variable 













Cardiovascular Disease    1.093** 1.024 1.166    
   CHF 1.390*** 1.270 1.521       
   Valvular Disorder 1.045 0.880 1.241       
   Peripheral Vascular Disease 1.070 0.928 1.233       
   Hypertension 1.011 0.949 1.077       
Respiratory System    1.286*** 1.196 1.383    
   Pulmonary Circulation 1.419** 1.148 1.755       
   Chronic Pulmonary 1.225*** 1.136 1.321       
Gastrointestinal    1.186* 1.019 1.381    
   Liver Disease 1.177 0.989 1.401       
   Peptic ulcer 1.154 0.846 1.572       
Neurological System    1.386*** 1.229 1.563    
   Paralysis 1.190 0.887 1.596       
   Other Neurological Disease 1.308*** 1.148 1.490       
Endocrine System    1.088* 1.013 1.168    
   Diabetes 1.097* 1.017 1.184       
   Hypothyroid 1.107 0.973 1.259       
Blood System    1.061 0.986 1.142    
   Coagulopathy 1.300* 1.020 1.655       
   Blood loss Anemia 0.807** 0.694 0.938       
   Deficiency Anemia 1.099* 1.010 1.196       
Substance Abuse    1.056 0.859 1.298    
   Alcohol Abuse 1.059 0.834 1.343       
   Drug Abuse 0.986 0.659 1.476       
Psychiatric    1.061 0.927 1.214    
   Psychosis 1.108 0.864 1.420       
   Depression 1.091 0.937 1.269       
Renal Failure 1.809*** 1.597 2.050 1.949*** 1.725 2.204    
Aids 1.171 0.584 2.349 1.176 0.586 2.357    
Obesity 1.074 0.918 1.255 1.077 0.922 1.259    
Rheumatoid Arthritis 1.211 0.946 1.552 1.189 0.929 1.522    
Weight loss 1.327*** 1.159 1.519 1.344*** 1.174 1.539    
Electrolyte 1.182** 1.085 1.288 1.199*** 1.101 1.305    
Total Comorbidity          
  0 (ref)       ref ref ref 
  1       1.118* 1.015 1.232 
  2+       1.504*** 1.384 1.634 
Stage of Cancer (late vs early) 1.074 0.994 1.160 1.067 0.988 1.152 1.063 0.985 1.148 
Second primary(yes/no) 0.867** 0.805 0.933 0.868** 0.807 0.935 0.855*** 0.794 0.920 
Sex (Male vs Female) 1.120** 1.052 1.193 1.115** 1.049 1.187 1.142*** 1.075 1.214 
Race (black vs white) 1.083 0.959 1.223 1.062 0.941 1.199 1.072 0.950 1.209 
Race (other vs white) 1.004 0.501 2.014 0.949 0.474 1.903 0.920 0.459 1.843 
Age or age group          
18 – 34 years (ref) ref ref ref ref ref ref ref ref ref 
35 – 44 years 0.829 0.437 1.573 0.836 0.441 1.585 0.821 0.433 1.557 
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45 – 54 years 1.001 0.559 1.793 0.986 0.551 1.765 0.978 0.546 1.750 
55 – 64 years 1.274 0.717 2.264 1.261 0.710 2.241 1.229 0.692 2.183 
65 + years 1.496 0.839 2.668 1.499 0.841 2.672 1.470 0.825 2.619 
Source of payment          
Private Payer (ref) ref ref ref ref ref ref ref ref ref 
Medicaid 1.300** 1.106 1.529 1.301** 1.107 1.529 1.334** 1.135 1.567 
Medicare 1.215** 1.087 1.357 1.218** 1.091 1.361 1.242** 1.112 1.388 
Military/Other 0.990 0.645 1.519 0.979 0.638 1.502 0.978 0.638 1.501 
Uninsured 1.179 0.935 1.488 1.174 0.930 1.481 1.180 0.935 1.488 
Appalachian 1.016 0.946 1.091 1.002 0.934 1.076 0.990 0.923 1.061 
Treatment          
No Treatment (ref) ref ref ref ref ref ref ref ref ref 
Chemotherapy Only 0.242*** 0.184 0.318 0.241*** 0.183 0.316 0.228*** 0.174 0.300 
Radiation Only 0.488** 0.294 0.810 0.483** 0.291 0.802 0.495** 0.298 0.822 
Surgery on Primary Site Only 0.340*** 0.296 0.390 0.339*** 0.296 0.389 0.329*** 0.287 0.378 
Chemotherapy and Radiation 0.367*** 0.285 0.473 0.365*** 0.283 0.471 0.341*** 0.265 0.439 
Surgery with Radiation 
and/or Chemotherapy 0.179*** 0.154 0.207 0.177*** 0.152 0.205 0.168*** 0.145 0.195 







Table 1-8. Cox Proportional Hazard models of Second Primary Cancer, 2,624 CRC patients 2003-2016 
 
Variable 













Cardiovascular Disease    1.057 0.949 1.179    
   CHF 1.670*** 1.393 2.002       
   Valvular Disorder 1.110 0.784 1.572       
   Peripheral Vascular Disease 1.010 0.747 1.365       
   Hypertension 0.981 0.879 1.095       
Respiratory System    1.285** 1.127 1.466    
   Pulmonary Circulation 1.299 0.806 2.095       
   Chronic Pulmonary 1.235** 1.079 1.415       
Gastrointestinal    1.258 0.977 1.621    
   Liver Disease 1.211 0.902 1.626       
   Peptic ulcer 1.308 0.804 2.130       
Neurological System    1.237 0.959 1.595    
   Paralysis 1.338 0.710 2.519       
   Other Neurological Disease 1.150 0.870 1.520       
Endocrine System    1.033 0.910 1.173    
   Diabetes 1.082 0.944 1.239       
   Hypothyroid 0.953 0.747 1.217       
Blood System    1.198** 1.057 1.358    
   Coagulopathy 0.950 0.576 1.568       
   Blood loss Anemia 0.921 0.713 1.189       
   Deficiency Anemia 1.236** 1.072 1.426       
Substance Abuse    1.543* 1.083 2.198    
   Alcohol Abuse 1.550 1.069 2.247       
   Drug Abuse 1.114 0.330 3.754       
Psychiatric    0.887 0.675 1.167    
   Psychosis 1.359 0.740 2.495       
   Depression 0.846 0.628 1.140       
Renal Failure 1.856*** 1.428 2.412 1.976*** 1.529 2.552    
Aids 
3.018 0.961 9.477 3.310* 1.058 
10.36
0 
   
Obesity 0.971 0.755 1.248 0.992 0.775 1.270    
Rheumatoid Arthritis 0.841 0.544 1.299 0.818 0.530 1.263    
Weight loss 1.319* 1.033 1.684 1.296* 1.015 1.654    
Electrolyte 1.173* 1.006 1.369 1.218* 1.046 1.420    
Total Comorbidity          
  0 (ref)       ref ref ref 
  1       1.106 0.951 1.285 
  2+       1.400*** 1.226 1.599 
Stage of Cancer (late vs early) 1.723*** 1.512 1.963 1.719*** 1.508 1.960 1.713*** 1.504 1.952 
Sex (Male vs Female) 1.159** 1.041 1.290 1.154** 1.039 1.281 1.175** 1.059 1.303 
Race (black vs white) 1.061 0.868 1.061 1.061 0.870 1.295 1.083 0.890 1.318 
Race (other vs white) 0.508 0.162 0.508 0.464 0.148 1.454 0.475 0.152 1.483 
Age or age group          
18 – 34 years (ref) ref ref ref ref ref ref ref ref ref 
35 – 44 years 0.757 0.292 1.961 0.758 0.293 1.962 0.753 0.292 1.946 
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45 – 54 years 0.609 0.247 1.500 0.607 0.246 1.495 0.581 0.236 1.429 
55 – 64 years 0.691 0.283 1.690 0.691 0.283 1.689 0.665 0.273 1.622 
65 + years 1.027 0.416 2.534 1.034 0.419 2.550 0.987 0.401 2.428 
Source of payment          
Private Payer (ref) ref ref ref ref ref ref ref ref ref 
Medicaid 1.522** 1.143 2.027 1.488** 1.118 1.980 1.595** 1.205 2.113 
Medicare 1.427** 1.181 1.724 1.444** 1.195 1.745 1.504*** 1.247 1.813 
Military/Other 1.907 0.936 3.885 1.800 0.884 3.666 1.863 0.916 3.787 
Uninsured 1.786** 1.304 2.445 1.798** 1.314 2.460 1.866*** 1.367 2.546 
Appalachian 1.129* 1.0001 1.275 1.121 0.994 1.265 1.068 0.949 1.202 
Treatment          
No Treatment (ref) ref ref ref ref ref ref ref ref ref 
Chemotherapy Only 1.494 0.857 2.604 1.507 0.865 2.624 1.591 0.916 2.765 
Radiation Only 1.812 0.503 6.526 1.436 0.427 4.835 1.602 0.481 5.334 
Surgery on Primary Site Only 0.568** 0.375 0.859 0.542** 0.359 0.819 0.543** 0.361 0.818 
Chemotherapy and Radiation 1.124 0.614 2.058 1.046 0.572 1.912 0.975 0.535 1.775 
Surgery with Radiation 
and/or Chemotherapy 0.477** 0.312 0.728 0.446** 0.293 0.680 0.443** 0.291 0.673 












Figure 1-2.  Kaplan Meier Survival Curves (Censoring and LifeTest) Comparing Early and Late Stage 








Many of the variables across all nine models in the Cox proportional hazard models were 
statistically significant; the all-cause mortality had the highest number of statistically significant 
variables. The individual comorbidities tended to have a larger effect size compared to the grouped 
system comorbidities and the overall comorbidity count, although some demographic/ patient factor 
effects tended to slightly increase as we moved across the models.  
In the all-cause mortality models, there were several personal factors that remained 
significant across all three models. The biggest effect was seen in late-stage (M1: HR= 3.198, 95% CI 
3.046-3.357, M2: HR= 3.211 95% CI, 3.058-3.371, M3: HR= 3.271, 95% CI 3.116-3.434).  What this 
means is that if a patient has late-stage CRC they have 3.198 / 3.211/ or 3.271 (corresponding to 
model progress 1-2-3) times the hazard of dying compared to those patients that have early-stage 
CRC. Others factors that remained significant and also had an increased hazard of all-cause mortality 
across all three models were 65 and older, Appalachian, males, black, having Medicaid, Medicare, 
Military/other, and uninsured compared to having a private payer insurance, weight loss, renal 
failure, aids, paralysis, and other neurological disease excluding paralysis . There were also protective 
findings. The smallest effect was seen in the treatment of surgery at primary site with radiation 
and/or chemotherapy (M1: HR= 0.118, 95%CI 0.108-0.128, M2: HR= 0.114 95%CI 0.105-0.124, M3: 
HR= 0.106 95%CI 0.098-0.115). What this means is that if a patient has the combination treatment of 
surgery with radiation and/or chemotherapy they have only 10.8% / 10.5% / or 11.8% (corresponding 
to model progress 1-2-3) of the hazard of dying compared to those patients that do not receive 
treatment. This is an average reduction of about 88% in the hazard of dying. Other protective factors 
that were seen across the model were hypertension, blood loss anemia, obesity, having a second 
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primary, being other race compared to white, and all treatments (chemotherapy only, radiation only, 
surgery at primary site only, chemotherapy and radiation, as well as the above mentioned surgery 
with radiation and/or chemotherapy. It is interesting that any treatment reduced the hazards of all-
cause mortality by 30% - 88% compared to having no treatment. The all treatment combination 
performed the best and radiation performed the worst, but all reduced the hazards of dying 
compared to no treatment.  Other comorbidities that were significant on the individual level, when 
grouped lost their effect. For example, CHF (HR= 1.566, 95%CI 1.467-1.672), peripheral vascular 
disease (HR= 1.157, 95%CI 1.044-1.281), and hypertension (HR= 0.929, 95%CI 0.892-0.968) were 
combined with valvular disorder (not found to be significant) and the protective finding of 
hypertension. The increased hazard of CHF and peripheral vascular disorder were washed out in the 
cardiovascular disease grouped mortality, which was not significant. The same is true with the 
endocrine system group where diabetes was individually significant and hypothyroidism was not, the 
effect was lost in the group.  Model 3, the aggregate count of comorbidity with the personal factors, 
all variables were significant except one age group, 55-64 years old. 
In the CRC mortality models, there were fewer comorbidities and clinical factors that were 
significant and the effects were not as high as all-cause mortality. The biggest statistically significant 
effect in CRC-cause mortality was in renal failure (M1: HR= 1.809, 95%CI 1.597-2.050), M2: HR= 1.949 
95% CI 1.725-2.204)).  This means is that if a patient has renal failure they have 1.809 or 1.949 times 
the hazard of dying from CRC mortality compared to those patients that do not have renal failure. 
Other factors that remained significant and also had an increased hazard of CRC mortality across all 
three models were CHF only and the aggregated category cardiovascular disease, both pulmonary 
circulation and chronic obstructive pulmonary disorders and the aggregated category respiratory 
system, neurological disorders but not paralysis and the aggregated category neurological system, 
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and diabetes only and the aggregated category endocrine system, weight loss, electrolyte disorders, 
being male, and having Medicaid or Medicare compared to a private payer insurance. Both aggregate 
counts of comorbidity were statistically significant, having one comorbidity increased the hazard of 
dying by 11.8% and having two or more comorbidities increased the risk of dying by 50.4% compared 
to those who have no comorbidities. There were also protective effects, the smallest of which, like 
that of all-cause mortality was seen in the treatment of surgery at primary site with radiation and/or 
chemotherapy (M1: HR= 0.179 95%CI 0.154-0.207, M2: HR= 0.177, 95%CI 0.152-0.205, M3: HR= 
0.168 95%CI 0.145-0.195). This means is that if a patient has the treatment combination of surgery 
with radiation and/or chemotherapy they have only 17.9% / 17.7% / or 16.8% of the hazard of dying 
compared to those patients who do not receive any of the three treatment options in this study 
(surgery, radiation, chemotherapy). This is an average reduction of about 82% in the hazard of dying. 
Other protective factors that were seen across the models were blood loss anemia, having a second 
primary, and like all-cause mortality, any treatment reduced the hazard of dying from CRC-specific 
mortality. All treatments reduced the hazard by at least 51%, ranging up to 82.1% reduction in the 
hazards by receiving some treatment compared to no treatment. What is interesting in this set of Cox 
models is that some effects are not present in variables that we would have expected, those were 
late-stage, age, Appalachian, and the uninsured.   
In the second primary malignancy models, there were some personal factors and 
comorbidities that were significant. The biggest effects were seen in renal failure (M1: HR= 1.856, 
95%CI 1.428-2.412, M2: HR= 1.976, 95%CI 1.529-2.552) and late-stage CRC (M1: HR= 1.723, 95%CI 
1.006-1.369, M2: HR= 1.719, 95%CI 1.508-1.960, M3: HR= 1.713 95%CI 1.504-1.952).  This means that 
if a patient has renal failure, they have 1.856 or 1.976 times the hazard of developing a second 
primary malignancy compared to those who do not have renal failure. The same is true for late-stage 
47 
 
CRC patients, they have 1.723 / 1.719/ or 1.713 times the hazard of having a secondary primary 
malignancy compared to those patients who have early-stage CRC. The other factors that were 
significant and had an increased hazard of all-cause mortality across all three models were CHF, 
chronic obstructive pulmonary disorder up to the grouped respiratory system, deficiency anemia up 
to the grouped blood system, substance use grouped only, weight loss, electrolyte disorders, being 
male, having Medicaid, Medicare, or uninsured compared to private payer insurance, and having two 
or more comorbidities compared to none. There were also protective findings. The smallest effect, 
like that of all-cause mortality was seen in the treatment of surgery at primary site with radiation 
and/or chemotherapy (M1: HR= 0.477, 95%CI 0.312-0.728, M2: HR= 0.446 95%CI 0.293-0.680, M3: 
HR= 0.443 95%CI 0.291-0.673). If a patient has the treatment combination of surgery with radiation 
and/or chemotherapy they have only 47.7% / 44.6% / or 44.3% of the hazard of dying compared to 
those patients that do not receive treatment. The other protective factor that were seen across the 
models was surgery at the primary site only reduced the hazard of dying from CRC-specific mortality. 
The only protective factors were treatment that included some sort of surgery compared to no 
treatment.  It is also really interesting that we did not see any statistically significant findings in any of 
the models of expected variables such as age groups, race, and any treatments that did not include 
surgery. Surgery has been shown to produce long-term survival rates and can be performed safely 
with low mortality.67, 68 Although the remaining treatments were non-significant, this was the only 
regression where any treatment at all compared to no treatment didn’t reduce the hazards. 
Chemotherapy, radiation, and the combination of both had a non-significant effect of increasing the 
hazards of secondary primary malignancy. The National Cancer Institute has noted that cancer 
treatments such as radiation and chemotherapy may increase the risk of second primary cancers, 
other studies have also found that having any combination of these cancer treatments increase the 
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likelihood of developing a second primary malignancy.69-71   While our results were not significant, it is 
in line with previous research and helps validate the results that we are seeing in this study. 
Comparing between the models, the mortality models seem to be much more similar to each 
other than the secondary primary model. Late-stage increased the hazard of dying in both mortality 
models and the secondary primary malignancy model, but was only significant in the all-cause 
mortality model. Obesity decreased the hazard of all-cause mortality and secondary primary but 
increased the hazard of CRC mortality. The individual comorbidities seemed to highlight the effect 
better than the collapsed and aggregate comorbidity count; some significant relationships of 
individual comorbidities were obscured through the process of aggregations. 
The Kaplan Meier survival curves (Censoring and LifeTest) comparing early and late-stage 
survival shows the vast difference between the two stages. The initial steep drop in the first 24 
months in late-stage is below 60% survival in this population of CRC patients compared to early-stage 
that dropped just below 90%. By 10 years, the late-stage survival was half of the early-stage survival 
at about 60% survival for early-stage and about 30% for late-stage. The 2015 U.S. combined CRC 
relative 5-year survival rates were 64% and 10-year was 58%3. Early-stage CRC has a 5-year survival 
rate of 90% but it declines to 71% and 14% for late-stages.3  The curves in this study are consistent 
with U.S. survival rates, further validating the results of the study. 
Limitations 
  There are several limitations to this study. The first is potential selection bias, there were a 
total of 28,229 patients identified by KCR that were diagnosed with initial primary CRC during the 
study time period. After missing data exclusions, the final total was 20,571 patients, an exclusion of 
7,658 or 23.1%% of the total identified patients. The missing comorbidities data could be due to the 
reality that many reporting hospitals are not part of the Commission of Cancer (CoC), a group that 
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requires comprehensive standardized data collection.19, 20   The second major limitation is the 
potential for comorbidities to be under reported to the registry. Comorbidities in the dataset are 
captured at the time of diagnosis. There is a potential that the reporting facility may not fully account 
for any comorbidities diagnosed prior to the primary CRC diagnosis.  Starfield et al, studied a small 
subset of Medicare patients and found that higher morbidity burden was associated with more 
medical visits.72  Another limitation in this study is the censoring of cases with cause of death coded 
as 777.7; the cause of death for these cases has been provided to KCR by the National Death Index 
which restricts use of data and cannot be released.73  It is unknown if the 777.7 coded cases could 
have had a CRC related mortality; all of those cases were censored, thus the results of the CRC 
mortality Cox proportional hazard models could be skewed. The last limitation is that this study 
included stage 0 CRC within the early stage group.  
Although progress has been made in the last few decades in understanding CRC, there is still a 
paucity of data examining the impact of comorbidities on cancer survival and secondary primary 
malignancies in relation to comorbidities. This research identifies that comorbidity burden increases 
the hazards of all-cause and CRC mortality. Further direction of research should be to examine the 
gap in knowledge of the role that comorbidity burden has on the standards of care and adherence to 




Paper 2: Spatio-temporal Analysis of Elixhauser Comorbidity Groupings and Stage of 




Colorectal cancer (CRC), includes any cancer that affects the large intestine of the 
gastrointestinal system, made up of the colon and rectum.7   Previously CRC had a low incidence rate, 
however it is now the third most common type of cancer and the third most common cause of cancer 
death among men and women in the United States.1-3   The American Cancer Society estimates that 
in 2020 there will be 147,950 new cases of CRC and 53,200 deaths from the disease in the U.S..3   
Kentucky had the highest CRC incidence in nation with 49.2 (per 100,000) for years 2012-2016 and 
ranked 5th in the nation in CRC mortality at a rate of 16.4 (per 100,000) for years 2013-2017.3-6 
We do not know the exact cause of CRC, however, there are many known risk factors 
associated with CRC2. The risk of developing CRC increases with age, adults over the age of 50 have 
the highest CRC burden than any age group.3, 10   Other known risk factors for CRC include family 
history, African American race, history of polyps, history of radiation therapy, inherited and 
inflammatory diseases, and lifestyle factors like low physical activity, smoking, alcohol consumption, 
obesity, and diets consisting of high-fat content.2, 7 
The Appalachian region includes the state of West Virginia and counties from 12 other states, 
including 54 counties in the eastern half of Kentucky.53, 54   Eastern Kentucky is markedly rural and less 
populated than other regions of the state, yet experiences higher rates of mortality and morbidity 
than the rest of the state.5   Health disparities have been well documented in rural Appalachia.5, 53 
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A comorbidity is defined as a disease or condition that exists simultaneously with another 
index condition of interest, in this study CRC is the index condition of interest.38, 39   The presence of 
comorbidity with an index condition, like CRC, has become increasingly more common with majority 
of the evidence supporting the highest comorbidity burden is concentrated in patients that are older, 
in minority groups, and living in poverty stricken areas.39    In this study, comorbidities will be looked 
at on an individual level, grouped level, and an Elixhauser comorbidity index count that can be found 
in table 2-1. The Elixhauser comorbidity index includes 29 individual comorbid conditions, that were 
initially selected and refined by examining the literature.41, 42   Rural Appalachia also experiences high 
prevalence rates of stroke, obstructive pulmonary disease, heart disease, and diabetes than non-
Appalachian areas.5, 53-55   The most prevalent comorbidity among CRC patients had been found to be 
diabetes.8, 9   Patients with diabetes have an estimated 25% increased risk of developing CRC 
compared to patients without diabetes.9 
 Socioeconomic, behavioral, and geographical factors exacerbate health disparities and 
disease in Appalachia.53, 55   Socioeconomic factors poverty, low literacy rates, lack of health insurance 
coverage, long traveling distances to healthcare providers, behavioral factors such as high rates of 
obesity and smoking, low physical activity, and environmental exposures can impact disease 
prevalence and screening in Appalachia.5, 53, 55, 74   The distribution of comorbidity across the state is 
easier to understand when looking at a map of disease information compared to typical research 
tables showing numeric data.58 
Geographic information systems (GIS) are used in epidemiological research to identify a visual 
location or “where” of disease.58   Spatial data in public health studies aids researchers in visualizing 
disease across geographic areas, allowing for easy identification of health trends over time.59, 60  
Spatial analysis can help to determine patterns or clusters in geographic areas that that can be used 
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to understand patient populations at higher risk and highlight areas for intervention in addressing 
health disparities.59, 60, 75 
The purpose of the current GIS project is to explore the impact of comorbidities on stage at 
diagnosis among CRC patients in Kentucky by examining geographical distribution of comorbidities 
and comparing maps of late-stage and cluster analysis. Those included were age 18 and older and 
diagnosed between January 1, 2003 and December 31, 2016. To date, there is no known study that 
has compared the geographical distribution of CRC stage at diagnosis and comorbidities across 
Kentucky or the nation. To address these gaps in the literature, we conducted secondary data analysis 
on CRC patients in Kentucky using data from the Kentucky Cancer Registry. The specific aim for this 
study was to perform a space-time cluster spatial analysis by mapping cases (late-stage) and controls 
(early) of patients by year of diagnosis across Kentucky and investigate geographical distribution of 
comorbidities across county at diagnosis. Depending on findings, recommendations for a systematic 
approach in using the clusters to identify geographic targets where public health interventions with 
screening would be recommended to help reduce the risk of late-stage diagnosis. Late-stage CRC is 
considered preventable.76   The outcomes of this study will hopefully highlight the geographic regions 
to target that could potentially reduce the number of late-stage diagnoses.  
Methods 
 
Study Design and Data Sources 
 
This is a matched case-control study of CRC cases in Kentucky. We started out with 28,229 
incident cases of primary CRC diagnosed between January 1, 2003 and December 31, 2016 and 
initially excluded a combined total of 7,658 cases due to missing information. Excluded cases were 
6,054 with missing morbidity information and 2,730 (1,126 of these were also missing morbidity 
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information and included in the above number) with missing stage, leaving a sample size of 20,571 
cases. Patients were then matched on a one to one basic by age group (18-49, 50-74, 75+ years) and 
sex (M/F) resulting in a total of 18,170 included patients, 9,085 late-stage cases matched to 9,085 
early-stage controls. All data were identified from the Kentucky Cancer Registry (KCR). Kentucky is 
funded by Surveillance, Epidemiology, and End Results Program (SEER) and National Program of 
Cancer Registries (NCPR); the umbrella program, North American Association of Central Cancer 
Registries (NAACR), independently evaluates data collected by KCR for completeness, accuracy, and 
timeliness.20, 27    Requested data from KCR included first cases of primary CRC. Included cases could 
have multiple primaries after initial their CRC, however, any cases with CRC as a primary cancer or 
metastasis after another cancer diagnosis was excluded. Approval for this study was granted by the 
University of Kentucky Institutional Review Board. 
Variables 
Sex, age at diagnosis, race, marital status at diagnosis, county at diagnosis, Appalachian status, 
vital status, best stage group, comorbidity diagnoses (up to 10 independent variables of ICD-9-CM 
diagnosis codes), and secondary diagnoses (up to 10 independent variables of ICD-10-CM diagnosis 
codes) were provided by KCR.  Age at diagnosis was categorized into three age groups, 18 - 49, 50 - 
74, and 75+ years. Race was categorized as white, black, and other. Marital status at diagnosis was 
categorized at married, single, or other. Primary payer was categorized as Medicaid, Medicare, 
military/other, private pay, and not insured. County at diagnosis was originally coded with a numeric 
identifier and then recoded to match the name of the county in Kentucky; all 120 counties in 
Kentucky were represented in the data.                      
Comorbidity was measured using the comorbidity and secondary diagnosis variables entered 
into the Healthcare Cost and Utilization Project’s Elixhauser Comorbidity Software (Version 3.7 for 
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ICD-9CM codes and the ICD-10-CM version) created by the Agency for Healthcare Research and 
Quality.41, 45    Diagnosis codes were processed using a SAS program macro that classifies Elixhauser 
Comorbidity variables, outputting individual binary variables for the 31 (Version 3.7)/29 Elixhauser 
morbidity groups. The final variables were combined to match the most up-to-date Elixhauser index. 
Exceptions include the omission of any cancer related comorbidities, and combination of the two 
diabetes categories (with and without chronic complications) into one. 
The Adult Comorbidity Evaluation-27 (ACE-27) index was also considered, but unfortunately 
available data did not allow us to grade severity within the ACE-27 index. Regardless, studies have 
shown that the Elixhauser measures outperform other comorbidity indices.46, 48, 49, 64, 66   Table 2-1 
shows the morbidity mapping used from ACE-27 groups to the Elixhauser Comorbidity index to the 
final inclusion of comorbidities (individual and grouped).  KCR comorbidity and secondary diagnosis 
variables include codes for patients known to have no morbidity (comorbidity diagnosis code of 0000 
or a secondary diagnosis entry of 0), patients with corresponding entries in either diagnoses code 
variables were treated as having no morbidity. Patients with a diagnosis code in the 
comorbidity/secondary diagnosis variables that did not match with an Elixhauser group were also 
treated as having no morbidity. Patients lacking comorbidity and secondary diagnosis data were 
considered to have unknown morbidity status and thus excluded from the study. Not all facilities 
reporting to KCR are part of the Commission of Cancer (CoC), a group that requires comprehensive 
standardized data collection including comorbidity information.19, 20  Stage was dichotomized to 
reflect early (stage 0, I, II) or late (III and IIII) stage disease.  Patients with unknown cancer stage was 
also excluded. Patients were then matched one-to-one on age group and sex by cancer stage (early or 
late). There were 2,301 more controls than cases and there were 100 cases that did not have enough 
controls to match in the corresponding age and sex groups. The 2,401 patients who did not have a 
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match were excluded. There were 9,085 cases and controls included in the final analysis. Figure 2-1 
shows the flow chart for patient inclusion and exclusion in the study. 
Statistical and Spatial Analysis 
The statistical software, SAS version 9.4 was used to examine patient demographics and 
disease characteristics, and fit a logistic regression model of late-stage diagnosis in relation to each of 
the Elixhauser-based comorbidity variables.21   A retrospective space-time cluster analysis using the 
Bernoulli case-control model constrained to clusters no larger than 35% of the population at risk and 
50% of the study period (2003-2016) was performed with SaTScan software.22    SaTScan was required 
to perform the analysis because standard GIS software packages do not have this function.61   The 
purpose of SaTScan cluster analysis was to perform a geographical surveillance of CRC to try to detect 
areas with high or low rates of significance (Figure 2-4).22    ArcGIS was used for mapping the 
comorbidities and proportion of cancers that were late-stage within each county, and mapping the 
cluster found in the SaTScan analysis.23   Thus we use both SaTScan and ArcGIS to complement to 
each other, we exported the cluster analysis file and joined to ArcGIS for mapping purposes.62  
Data were aggregated based on county. The number of aggregated late-stage cases within 
each county were then divided by the total of cases and controls (early-stage) within each county, 
this gave us the proportion to map. The comorbidity maps were designed the same way, individual 
comorbidity aggregated counts were divided by the total number of cases and controls in each 
county, and combined late and early-stage percentage of two or more comorbidities were also 
treated this way. All maps used the data classification of Jenks natural breaks. Natural breaks are data 
specific classifications that are based on natural groupings within the data with similar values, they 




Table 2-1. Morbidity Mapping ACE-27 Index, Elixhauser, and Final Inclusion Study Comorbidity and 
Groupings 
Ace-27 Index  Elixhauser  ICD 10* Final Inclusion 
Cardiovascular System 
Myocardial Infarct  
Angina / Coronary Artery Disease 




Peripheral Arterial Disease 
Respiratory System 
Restrictive Lung Disease or COPD  
Other markers not diagnoses 
Gastrointestinal System 
Hepatic 
Stomach / Intestine 
Pancreas 
Renal System 
End-stage renal disease 








Recent suicidal attempt 
Schizophrenia 




Mixed Connective Tissue Disorder 
Polymyositis  
Rheumatic Polymyositis 
Immunological System  
AIDS 
Malignancy  
Solid Tumor including melanoma 
Leukemia and Myeloma 
Lymphoma  
Substance Abuse  
Alcohol 
Illicit Drugs  
Body Weight 
Obesity 
Congestive Heart Failure 
Valvular disease 
Pulmonary circulation disorders 
Peripheral vascular disease 
Hypertension (Complicated & 
Uncomplicated) 
Paralysis 
Other neurological disorders 






Chronic peptic ulcer disease 
HIV and AIDS  
Lymphoma 
Metastatic cancer 
Solid tumor without metastasis 





Fluid and electrolyte disorders 














Congestive Heart Failure 
Hypertension  
Peripheral Vascular Disorder 
Valvular Heart Disease 
Respiratory System  
Pulmonary Circulation Disorders 
Chronic Pulmonary 
Gastrointestinal System  
Liver Diseases 
Peptic Ulcer Disease  
Renal System  
Renal Failure 
Endocrine System  
Diabetes (Complicated & Uncomplicated)  
Hypothyroidism 
Neurological System  
Paralysis 






Immunological System  
AIDS/HIV 
Substance Abuse  
Alcohol Abuse 
Drug Abuse 
Body weight  
Obesity 
Blood System  
Coagulopathy 
Blood Loss Anemia 
Deficiency Anemia 
Remain but not grouped 
Weightloss 
Fluid & Electrolyte Disorders 
*Elixhauser ICD-9 (31 Variables) conversion to ICD-10 (29 Variables) version changes: Removal of Cardiac Arrhythmia and 
Combining of Hypertension with and without complications. Some data were collected prior to the 2015 ICD-10 activation, 




Table 2-2. Patient Demographics 
Demographics Early Stage (I-II)  
(N=9085) 
Late Stage (III – IV) 
(N=9085) 
Age     
18 - 49 years 
50 – 74 years 













































Diabetes  1,998 (21.99%) 1,653 (18.19%) 
Renal Failure 362 (3.98%) 290 (3.19%) 
Liver Disease 277 (3.05%) 328 (3.61%) 
CHF 780 (8.59%) 601 (6.62%) 
Hypertension 4,983 (54.85%) 4,053 (44.61%) 
Appalachian 2,462 (27.10%) 2,570 (28.29%) 
Total Comorbidity Groups 






























The choropleth morbidity maps, found in Figure 2-2, show the geographical distribution of the 
four individual comorbidities, electrolyte disorders, liver disease, weight loss, and deficiency anemia 
across Kentucky. The four maps do not demonstrate any geographical patterns in the distribution of 
comorbidities. The map of comorbidities among CRC patients is displayed in Figure 2-3. This map 
shows that a large percentage of CRC patients experience two or more comorbidities, but does not 
demonstrate a strong pattern of disease.  
The percentage of late-stage cancer by county appears in Figure 2-4 with a retrospective 
space-time cluster analysis utilizing SaTScan found one cluster with the highest likelihood and 
statistically significant high-rate cluster of late-stage CRC in southeastern Kentucky. The time period 
for this cluster was limited to January 1, 2013 to December 31, 2016. This map does not exhibit a 
strong geographical pattern of late-stage cancer, but does show there is a high burden of late-stage 
CRC within the majority of the counties and within the cluster area.  There were 751 total observed 
late-stage cases, while the expected number of late-stage cases was only 612.5, a ratio of 1.23 
observed late-stage diagnoses for each one expected(p <0.0001).  
 The bivariate model results in Table 2-2 show that some individual comorbidities had a 
protective effect with regard to late-stage diagnosis of CRC, while other comorbidities appeared to be 
a risk factor for late-stage diagnosis of CRC. The individual comorbidities with statistically significant 
reduced odds of late-stage CRC were found in CHF (OR= 0.754, 95% CI 0.675-0.842), valvular disorder 
(OR= 0.725,95% CI 0.597 - 0.881), peripheral vascular disease (OR= 0.762, 95% CI 0.644 - 0.902), 
hypertension (OR= 0.663, 95% CI 0.625 - 0.703), neurological disorders excluding paralysis (OR= 
0.821, 95% CI 0.706 - 0.956, chronic obstructed pulmonary disease (OR= 0.746, 95% CI 0.688 - 0.809, 
diabetes (OR= 0.789, 95% CI 0.734 - 0.849, hypothyroidism (OR= 0.769, 95% CI 0.679 - 0.871), obesity 
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(OR= 0.774, 95% CI 0.682 – 0.879), and renal failure (OR= 0.795, 95% CI 0.679 - 0.930. The individual 
comorbidities with statistically significant increased odds of late-stage CRC were found in liver disease 
(OR= 1.191, 95% CI 1.012 - 1.401, weight loss (OR= 1.593, 95% CI 1.400 - 1.813), electrolyte (OR= 
1.187, 95% CI 1.087 - 1.296, and deficiency anemia (OR= 1.113, 95% CI 1.033 - 1.199. When 
aggregating the total number of individual morbidities, grouped as 0, 1, or 2+ comorbidities, having a 
comorbidity had a protective effect against the odds of late-stage diagnosis of CRC compared to 
those without a comorbidity. Having one comorbidity (OR= 0.504 95% CI 0.463 - 0.550) reduced the 
odds of late-stage diagnosis of CRC by 49.6% and having two or more total comorbidities (OR= 0.534, 
95% CI 0.494 - 0.578) reduced the odds of late-stage diagnosis of CRC by 46.6% compared to those 







Figure 2-2. Choropleth mapping percentage of Kentucky CRC patients diagnosed with individual 




Figure 2-3. Kentucky CRC patients having been diagnosed January 1, 2003 – December 31, 2016 
with 2 or more comorbidities by county  
 
Figure 2-4. Late Stage CRC by County and Retrospective Space-Time Analysis High Rate Cluster of 





Table 2-3. Elixhauser Based Morbidity Bivariate 
Elixhauser Bivariate Late Stage (III – IV)  
(Event =1) OR (95% CI) 
CHF 0.754  (0.675 - 0.842)*** 
Valvular Disorder 0.725  (0.597 - 0.881)** 
Pulmonary Circulation 0.911  (0.713 - 1.164) 
Peripheral Vascular 0.762  (0.644 - 0.902)** 
Hypertension 0.663  (0.625 - 0.703)*** 
Paralysis 0.892  (0.609 - 1.308) 
Neurological 0.821  (0.706 - 0.956)* 
Chronic Pulmonary 0.746  (0.688 - 0.809)*** 
Diabetes  0.789  (0.734 - 0.849)*** 
Hypothyroid 0.769  (0.679 - 0.871)*** 
Renal Failure 0.795  (0.679 - 0.930)** 
Liver Disease 1.191  (1.012 - 1.401)* 
Peptic ulcer 1.040  (0.757 - 1.430) 
Aids 1.154  (0.549 - 2.426) 
Rheumatoid Arthritis 0.857  (0.652 - 1.126) 
Coagulopathy 1.093  (0.830 - 1.440) 
Obesity 0.774  (0.682 - 0.879)*** 
Weight loss 1.593  (1.400 - 1.813)*** 
Electrolyte 1.187  (1.087 - 1.296)** 
Blood loss Anemia 1.014  (0.877 - 1.173) 
Deficiency Anemia 1.113  (1.033 - 1.199)** 
Alcohol Abuse 0.944  (0.747 - 1.194) 
Drug Abuse 0.804  (0.532 - 1.214) 
Psychosis 1.099  (0.827 - 1.460) 
Depression 0.969  (0.849 - 1.105) 






0.504  (0.463 - 0.550)*** 
0.534  (0.494 - 0.578)*** 
* p < 0.05 ;   ** p < 0.01 ;   *** p < 0.0001 
 
Discussion 
While the results show that comorbidities are associated with a lower risk of late-stage 
disease, and that there is a cluster of counties in the southeastern region of Kentucky with a higher 
proportion of late-stage cancer cases than expected, the study did not discern a geographical pattern 
suggesting that comorbidities were similarly distributed. It seems more likely that other factors are 
driving the higher rates of late-stage CRC in these counties.   
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There is no clear indication from the data of what might be driving the higher rates of late-
stage CRC in the cluster, however, more complete records for the excluded cases may have provided 
more information to the area, as just over 40% of the excluded records were from Appalachian 
counties. There are inherit barriers in the Appalachian area that has long been acknowledged as 
issues related to disparities in CRC screening. CRC screening barriers in this area is complex and 
interrelated to each other, from cultural beliefs and values, demographic factors, and psychological 
factors surrounding CRC and screening.56, 78, 79  There are knowledge gaps, which can be related to not 
knowing family history, having a less than high school education, and males in general having overall 
low knowledge about CRC.78, 79  There is also a cultural and religious belief that while medical exams 
are important, the more men knew about CRC screening involves they no longer related the exam 
with health, rather they associated the screening negatively because they believe the invasiveness of 
the experience relates to their masculinity.78-80   
While the maps do not show that there is a pattern of comorbidity corresponding to the 
cluster, they do show that a large percentage of patients diagnosed with initial primary CRC 
experience disproportionate rates of comorbidities. The map of aggregate comorbidities does not 
appear distributed in any particular pattern, but shows that more than half of CRC patients have 
multiple comorbidities in a majority of counties (73 out of 120).   
There are several limitations to this study. The first is potential selection bias. There were 
28,229 patients diagnosed with first primary CRC during the study time period that were identified by 
KCR. After removals due to missing data, comorbidities and stage at diagnosis, and the inability to 
matched one to one (cases and controls) on age and sex, the final total was 18,170 patients, an 
exclusion of 10,059 or 35.6% of the total identified patients. One reason for the large amount of 
missing comorbidities could be because many of the facilities reporting may not be hospitals that are 
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part of the Commission of Cancer (CoC) with comprehensive standardized data collection.19, 20   
Another major limitation of the study is the notion of ecological fallacy. Association observed at an 
aggregated scale may not always exist at the individual scale; given the aggregated nature of data in 
this study, ecological fallacy is likely present.81   We can see from the bivariate logistic regression that 
there are statistically significant associations between late-stage diagnosis and several individual 
comorbidities. The third limitation is the likelihood of the under-ascertainment of comorbidities. 
Documented comorbidities are from the time of diagnosis, the comorbidities identified from the 
reporting facility and physician may not fully capture all comorbidities that the patient had been 
diagnosed with prior to the diagnosis of primary CRC. Administrative data has been found to be 
associated with under-reporting number of comorbidities compared to chart reviews and clinical 
billing codes.82  There were other clusters found in addition to the one reported, however, the one 
reported was the hierarchically the cluster with the highest likelihood.22  The other clusters were not 
reported in this study because they are considered secondary.22  
The logistic regression did have statistically significant results related to individual and 
grouped comorbidities. Those comorbidities with reduced odds of late-stage CRC were CHF, valvular 
disorder, hypertension, peripheral vascular disease, neurological disorders excluding paralysis, 
chronic obstructed pulmonary disease, diabetes, hypothyroidism, and renal failure.   The 
comorbidities with increased odds of late-stage CRC diagnosis were liver disease, weight loss, 
electrolyte disorders, and deficiency anemia. In the aggregated comorbidity variable, those CRC 
patients with one or more comorbidities has statistically significant higher odds of late-stage CRC 
compared to those CRC patients with no comorbidity.   A study by Starfield et al, examined the 
impact of comorbidity on the use of primary and specialty care services, finding that higher morbidity 
burden was associated with more medical visits in a small subsample of Medicare beneficiaries.72  
66 
 
Perhaps there is a potential for the types of comorbidities that provide a protective effect 
from late-stage CRC require less focus and time from a physician, offering the patient an opportunity 
to mention other symptoms that may trigger a physician to screen a patient for cancer.83, 84   It may 
also be that patients with these comorbidities return regularly for routine health checks, and thus 
have more opportunities for screening. On the other hand, it is possible that comorbidities associated 
with increased odds of late-stage diagnosis have “competing demand”, where a physician’s time and 
vigilance are focused on dealing with complex comorbidities that require urgent attention and 
interfere with preventive services like cancer screening.83, 84   Further research into comorbidities and 
CRC are needed. In particular chart reviews and examination of clinic billing codes could aid in 
determining the number of times a patient sought care, and how long they had been diagnosed with 







This research aimed to 1) characterize the patient factors of socio-demographic and 
comorbidity by stage of diagnosis, 2) examine if comorbidity status is associated with mortality and 
the development of second primary cancers, and 3) to perform a space-time cluster analysis of late-
stage at diagnosis to investigate its relationship with comorbidities at the population level. The 
results of the two studies are varied. Based on the bivariate regression analysis in both the GIS and 
research paper, comorbidity burden does seem to play a role in predicting stage, many of the 
individual comorbidities are protective, or have reduced odds of late-stage CRC. The Cox hazard 
regressions show that many of the individual comorbidities have an increased hazard of all-cause and 
CRC mortalities. There does appear to be a dose-response relationship in the Cox models, suggesting 
that the progression from individual to aggregated comorbidities there is a relationship with having 
any comorbidity and the outcome of mortality. The space-time analysis found a significant high rate 
cluster of late-stage CRC, however, mapping the distribution of positively associated comorbidities, 
individually or in aggregate count, did not demonstrate a pattern matching the cluster.  
 The results indicate that comorbidities do play a role in the stage of CRC diagnosis, 
perhaps curiously, there are greater odds of being diagnosed with early-stage cancer for many of the 
individual comorbidities. On the other hand, the results also indicate that some comorbidities 
increase the hazards of mortality and second primary malignancy. Although there is a defined cluster 
of higher than expected late-stage CRC in southeastern and eastern Kentucky, at this aggregate level, 
the results do not indicate that there is a geographically distributed pattern of comorbidities that 
appear to affect the CRC cluster. The results do show nonetheless that there is a larger number of 
CRC patients across a majority of Kentucky counties who suffer from comorbidity burden. 
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There were noted limitations of selection bias, ecologic fallacy, and potential under-
ascertainment of comorbidity information for the cases. There was a high percentage of cases 
excluded to missing data with a high percentage from Appalachia. Perhaps more complete data from 
Appalachia would have shed light on the area where the space-time CRC cluster was discovered. 
Further research is needed to examine why having certain comorbidities would be protective 
of late-stage diagnosis, could those patients be more likely to visit a doctor and therefore have a 
higher likelihood of being screened for cancer than the people who did not have these protective 
comorbidities? Further research needs to be done to try to determine what factors are driving the 
high rates of CRC in the area of the indicated cluster.  Future research topics should include 
investigating the number of times CRC patients sought care, and how long they’d been diagnosed 
with comorbidities before CRC diagnosis, this would allow a Cox regression model to examine a time 
to event, the time a patient was diagnosed with a comorbidity until the time they were diagnosed 
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